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Role of the integrin α5β1 in cell migration in a model of metastatic breast cancer 
 




Background: Metastasis is the leading cause of breast cancer mortality and is the result of the interplay 
between cancer cells and the surrounding microenvironment, which is regulated by complex molecular 
networks and involved numerous genes. Matrix components and many extracellular matrix (ECM) proteins, 
such as fibronectin (FN), promote tumor progression and metastatic spread. Integrins are cell-surface 
adhesion receptors that interact with ECM components have been reported to contribute to tumor growth, 
cell adhesion, invasion, and metastasis.  
Aim: The purpose of this study was to characterize the role of integrin α5 (ITGA5) and integrin β3 (ITGB3) 
in cell migration in a model of metastatic breast cancer.  
Methods: ITGA5 and ITGB3 expressions were invalidated using siRNA in MDA-MB-231 cells. To 
achieve a stable knockdown, ITGA5 and ITGB3 invalidation as also performed using shRNA. First, the 
levels of mRNA and protein were assessed to confirm the effectiveness of the invalidation. Second, impacts 
of integrin invalidation were evaluated on phenotype characteristics, cytotoxicity, and migratory capacity. 
Results: Effective invalidation of ITGA5 and ITGB3 using siRNA, with a strong effect on the migratory 
capacity in ITGB3 invalidated cells. On the other hand, the ITGA5 knockdown using shRNA was effective 
in the case of sh126, but it was not for sh124. No differences were observed at the morphological level. A 
difference in the confluency was observed without a toxicity effect, suggesting a decrease in cell adhesion. 
During the second part of the study a cell adhesion test was carried out, which did not show conclusive 
results. Additionally, ITGA5- and ITGB3-invalidated cells were further characterized on uncoated and FN-
coated surfaces. A new ITGA5-targeting shRNA was tested, giving a very strong phenotype that did not 
allow cell characterization. ITGB3 knockdown was performed using shRNA previously tested in the 
PACMAN project, which covers this study. FN-coating showed an effect on the cells. It triggered the 
clusterization of ITGA5 and induced change in cell size, indicating a higher adhesion to the surface. Finally, 
cells were co-invalidated for ITGA5 and ITGB3, leading to a lower adhesion. Nevertheless, the focal 
adhesion formation was observed in all the cases studied.  
Conclusion: ITGA5 invalidated cells did not show a significant difference in their migratory capacity. A 
further characterization of the role of the integrins in cell migration will allow to identify 
therapeutic/diagnostic targets against advanced breast cancer. 
Keywords: Cell migration, Integrins, α5β1, αvβ3, metastasis 
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This thesis is written as the completion to the Master of Biomedical Sciences, at the University of 
Namur. This project was done at Laboratory of Cellular Biochemistry and Biology (URBC) within 
the TumHyp team lead by Prof. Carine Michiels.  
This study focused on the role of the integrin α5β1 in cell migration in a model of metastatic breast 
cancer. In order to facilitate the understanding of the experiments and results obtained, this work 
will start with an introduction containing a series of information and theoretical notions relevant 
to the study. 
First, with cancer being a leading cause of death worldwide, it is an important research focus in 
the medical field. Cancer is a group of diseases that can affect almost any part of the body. It is an 
uncontrolled growth, that often invades surrounding tissue and spread to other organs1. This latter 
process is denominated metastasis.  
Chapter 1 contains the information about breast cancer, the study focused on this cancer type 
because is the most frequently diagnosed cancer, with approximately 2.09 million cases in 2018, 
and the leading cause of cancer death in women worldwide1. Then, to understand the cancer 
progression and metastasis, chapter 2 explains the cell adhesion process and the role of the actors 
involved. The chapter brings key information about the interaction of some cell adhesion 
molecules and the extracellular matrix. It also describes, how the abnormal functioning of those 
molecules could entail to different processes related to metastasis and alter the interactions with 
the different compounds of the microenvironment.  
Following, chapter 3 talks about metastasis, which is a complex process with great importance 
because it remains to be a big problem in the clinical management of cancer since a major cause 
cancer mortality is associated with the disseminated disease rather than with the primary tumor2. 
Chapter 3 explains the steps involved in this process and its relevance within the frame of breast 
cancer. Afterward, chapter 4 presents integrins and their characteristics in cancer progression and 
metastasis. Integrins are some of these cell adhesion molecules to extracellular matrix (ECM). 
Specifically, this section elucidates the current knowledge about integrins α5 (ITGA5) and β3 
(ITGB3) in relation to cancer, which are the focus of this study.  
Finally, chapter 5 finishes with the description of the PACMAN (Peptide-Assisted Cellular 
Migration Along eNgineered surfaces) project, which is a research project aiming to characterize 
and compare the static and different migratory phenotypes in a way to identify pathways involved 
in cell migration induced by the activation of integrins α5β1 and αvβ3, and within which this thesis 
































1. Breast cancer  
Breast cancer results from the proliferation of malignant cells derived from epithelial cells that 
coat the breast ducts or lobules. This is a clonal and unique disease, where a cell, through a series 
of somatic or germline mutations, acquires the ability to divide without control, forming a tumor. 
The development of breast cancer involves a progression through intermediate stages. Then, it 
becomes severe as an invasive carcinoma, finally resulting in a metastatic disease, when it spreads 
to other parts of the body3. Breast cancer is characterized by heterogeneous cell populations. This 
heterogeneity causes different problems in therapeutic medicine. Notably due to its complex 
etiology and uncomplete understanding of its genesis4. 
1.1. Epidemiology and risk factors  
Breast cancer is the cancer with the highest incidence among women worldwide. This disease is 
the most frequently diagnosed cancer and the leading cause of cancer death in that population5. 
Consequently, breast cancer is becoming a major public health problem6. According to Globocan 
statistics, over 1.7 million new breast cancer cases were diagnosed in 2012, accounting for 25% of 
all cancer morbidities among females worldwide4. Current predictions and statistics suggest that 
incidence and related mortality are on the rise around the world7. However, the incidence of breast 
cancer significantly varies around the world; for example, it is markedly higher in developed 
countries. Also, an estimated 60% of breast cancer deaths are now thought to occur in the 
developing world6.  
There are some risk factors for breast cancer. First, it is strongly related to age with only 5% of all 
breast cancers occurring in women under 40 years old8. Second, the lifestyle plays a major role. 
For example, the number of cases worldwide has significantly increased in the last 50 years. This 
phenomenon could be attributed to the modern lifestyle (obesity, drinking alcoholic beverages, 
smoking and exposure to ionizing radiation). Third, the increased exposure to endogenous estrogen 
due to reproductive factors such as a late menopause. Also, nulliparity, lack of breastfeeding or 
the use of combination estrogen-progesterone hormones after menopause have been shown to be 
associated with the diseace9. Finally, genetic susceptibility is the primary cause of 5–10% of all 
cases10.  
1.2. Classification  
Breast cancer is classified by several grading systems. Histopathology, grade, stage, receptor status 
and DNA mutational status are such examples. The classification determines the prognosis, the 
selection of the best treatment and its response.  
1.2.1. Histopathology 
It is based on characteristics observed upon microscopy of biopsy specimens. The two most 
common histopathological types are carcinoma in situ and invasive carcinoma. First, in carcinoma 
in situ, cancer cells proliferate within the epithelial tissue without invade neighboring tissue. It 
accounts for 13% of breast cancers. Contrarily, invasive carcinoma can spread outside the breast 




invasive ductal carcinoma, accounting for 55% of breast cancers, and invasive lobular carcinoma, 
accounting for 5% of the cases11.  
1.2.2. Stage 
 Cancer staging is the process of determining how much cancer is in the body and where it is 
located. It helps to describe the severity of an individual's cancer based on the magnitude of the 
original (primary) tumor as well as on the extent cancer has spread in the body12. The assessment 
uses the TNM staging system, that is a classification system developed as a tool for doctors to 
stage different types of cancer, based on certain, standardized criteria. The TNM staging system is 
based on the extent of the tumor (T), the extent of spread to the lymph nodes (N) and the presence 
of metastasis (M)12. Larger size, nodal spread and metastasis have a higher stage number and a 
worse prognosis13. The lowest stage is the stage 0, describing non-invasive cancers that remain 
within their original location, they are pre-cancerous, either ductal carcinoma in situ (DCIS) 
or lobular carcinoma in situ (LCIS). It is followed by the stages 1–3, those tumors are within the 
breast or regional lymph nodes. At last, stage 4 describes invasive cancers that have spread beyond 
the breast and regional lymph nodes to other parts of the body. These metastatic cancers have a 
less favorable prognosis14.  
1.2.3. Grade 
This classification depends on the degree of differentiation of the tumor tissue. It refers to the semi-
quantitative evaluation of morphological characteristics of the tumor malignancy and 
aggressiveness.  Pathologists describe cells as well differentiated (low grade), moderately 
differentiated (intermediate grade) or poorly differentiated (high grade) as the cells progressively 
lose the features seen in normal breast cells15.  
1.2.4. Receptor status 
Breast cancer cells express receptors on their surface and in their cytoplasm and nucleus. The 
estrogen receptor (ER) and progesterone receptor (PR) status is of critical interest in determining 
the prognosis of breast cancer patients and the potential benefit of adjuvant hormonal therapy16. 
Their status is routinely assessed as well as the Human epidermal growth factor receptor 
2 (HER2) status that is also a prognosis marker, where HER2+ breast cancers are generally more 
aggressive than HER2- breast cancers. This marker, HER2+, determines patient eligibility to 
monoclonal antibody trastuzumab therapy17. Triple negative breast cancer is characterized by lack 
of expression of these three receptors: estrogen, progesterone and HER2 receptors, although these 
tumors frequently do express receptors for other hormones, such as androgen 
receptor and prolactin receptor18. Clinically, these cases are characterized by greater 
aggressiveness, frequent rate of local recurrence and organ metastases. They are associated with 
the occurrence of hereditary forms of breast cancer caused by pathogenic mutations in the BRCA1 
gene or in rare cases, BRCA219 they are more common in younger women. Therefore, most triple-






1.2.5. Mutational status 
In cancer, some changes in DNA sequence, known as driver mutations, confer proliferative 
advantages to those cancer cells. Driver mutations can be inherited in the germline, but most of 
them appear in somatic cells during the lifetime of the patient. In addition, many temporary 
mutations that are not involved in cancer development also arise 21.  
The cases due to a hereditary predisposition are just a small percentage. However, gene signatures 
have been developed as predictors of response to therapy and protein gene products. Those 
implicated genes have direct roles in driving the biology and clinical behavior of cancer cells and 
are potential targets for the development of novel therapeutics22.  
Two genes, BRCA1 and BRCA2, are linked to a rare familial form of breast cancer. Women whose 
families have mutations in these genes have a higher risk of developing breast cancer23.  
Additionally, the mutation of the p53 oncogene, characteristic of the Li-Fraumeni syndrome, has 
been connected to the disease24. These mutations would determine approximately 40% of the cases 
of hereditary breast cancer.  
Other inherited mutations that increase the risk of cancer include mutations of the PTEN gene 
(Cowden syndrome) of STK11 (Peutz-Jeghers syndrome) of CDH1. The majority of breast cancer-
susceptibility genes code for tumor suppressor proteins that are involved in critical processes of 
DNA repair pathways25. Its frequency and increased risk for breast cancer are not yet known 
exactly. In more than 50% of cases, the gene associated with inherited breast cancer is unknown. 
To analyze the complete panorama, that involved inherited and non-inherited mutations, 560 
genomes of patients with breast cancer were sequencing to study all classes of somatic mutation 
across exons, introns, and intergenic regions. As a result, five new cancer genes were identified 
(MED23, FOXP1, MLLT4, XBP1, and ZFP36L1)21. This study highlights the repertoire of cancer 
genes and mutational processes.  
1.3. Prognosis  
The stage of the breast cancer is the most important component of conventional classification 
methods of breast cancer, because it has a greater effect on the prognosis than the other 
classification.  This disease heterogeneous in clinical, pathological and genetical characteristics 
shows that the poor prognosis and the cause of death in the majority of patients are related to the 
metastatic lesions26. Despite major advances in understanding the molecular and genetic basis of 
cancer, metastasis remains the cause of the vast majority of cancer-related mortality27. The spread 
of cancer cells throughout the body represents the central clinical challenge of solid tumor 
treatment. A deeper understanding of the mechanisms underlying the metastatic process and the 
complex interactions between tumor and host during disease progression has been widely 







2. Cell adhesion 
 
Cell adhesion is an essential process for tissue development, structure, and maintenance in 
multicellular organisms29. Also, cell adhesion is involved in cell migration and proliferation. Cell-
to-cell and cell-to-matrix adhesion are the interactions by which cells attach to other cells or to 
extracellular components through specialized molecules of the cell surface29. Additionally, cell 
adhesion provides a mechanism for intercellular communication and signal transduction, in order 
to detect and respond to changes in the microenvironment. Alteration in cell adhesion can affect 
different cellular processes and lead to a diverse kind of diseases, including cancer30. Understand 
its complexity is crucial for the study of cancer progression and metastasis.  
 
2.1. Cell adhesion molecules  
 
Cell adhesion molecules (CAMs) are transmembrane glycoproteins that mediate cell-cell and cell-
matrix interactions and also serve as the receptor for different kinds of virus31. They are essential 
for transducing intracellular signals responsible for the cytoskeletal organization, cell growth, 
differentiation, site-specific gene expression, morphogenesis, immunologic function, 
inflammation, adhesion, migration, invasion, angiogenesis, and organ-specific metastasis32.  
 
Four of the major groups of cell adhesion molecules are the immunoglobulin superfamily (Ig-
CAMs), the integrins, the selectins, and the cadherins.  CAMs bind to other cells or matrix 
components through their interaction with the corresponding ligands. In some cases, those ligands 
can be CAMs themselves33 (Figure 1).  
 
 
Figure 1. Major families of cell-adhesion molecules (CAMs). The main groups that mediate cell-cell and cell-
matrix adhesion: the immunoglobulin superfamily (ig-CAMs), the integrins, the selectins, and the cadherins. 




2.1.1. Immunoglobulin superfamily  
The immunoglobulin superfamily (Ig-CAMs) is the most diverse superfamily of CAMS. They are 
expressed in many different cell types, including cells of the nervous system, leukocytes and 
epithelial, and endothelial cells. This characteristic implies the wide variety of biological processes 
that Ig-CAMS have in the organism, such as brain development, immune responses, tissue sorting, 
epithelial morphogenesis and the development of the vascular network34. This family is 
characterized by the presence of one or more Ig-like domains in the extracellular region of the 
protein. Additionally, the ectodomain can have fibronectin type III (FNIII) repeats33.  
2.1.2. Cadherins  
 
This superfamily is the main mediator of calcium-dependent cell-cell adhesion. This process is 
accomplished by homophilic protein-protein interactions between two cadherin molecules at the 
surface of the respective cell, with a link to the actin filament network34. They are the principal 
components of adherent junctions and desmosomes. Their biological functions are diverse and 
include the regulation of cell recognition, tissue morphogenesis, tumor progression, synapse 
formation and synaptic activity32. Cadherins play an important role in the migration of cells during 
the epithelial-mesenchymal transition (EMT). For example, E-cadherin is an epithelial marker and 
N-cadherin is a mesenchymal marker of the EMT process31. 
 
2.1.3. Selectins 
Selectins (E-selectin, P-selectin, and L-selectin) are a family of heterophilic CAMs that are 
dependent on fucosylated carbohydrates. Those indispensable for binding of circulating 
leukocytes to vascular endothelium during the inflammatory response to injury or infection33. 
2.1.4. Integrins 
Integrins are the major cell-surface adhesion receptors to the extracellular matrix (ECM). They are 
a family of 24 transmembrane heterodimers constituted of 18 α and 8 β subunits35 (Figure 2). 
Integrins mediate cell adhesion and directly interact with ECM components, providing anchorage 
for cell adhesion, proliferation, motility, survival and invasion36. Integrins are classified into 
receptors recognizing Arg- Gly-Asp (RGD) peptide motifs, collagen receptors, laminin receptors 
and leukocyte-specific integrins37.  Integrin expression is dynamic during the multiple cellular 
processes where they take part, including cell adhesion, migration, proliferation, survival and the 
activation of growth factor receptors36. In cancer, integrins contribute to tumor growth, cell 







Figure 2 Integrins subunits interactions. The integrin family contains 24 heterodimers constituted of 18 α and 8 
β subunits. From Li, Y. et al. Breast Cancer Res (2015).  
2.1. Cell-cell interactions 
 
Cell-cell adhesion is indispensable for the physiological function of a cell and its integration in 
functional structures, such as organ epithelia or stroma34. The intercellular junctional complex is 
compound by three types of adhesion junction: tight junctions, adherens junctions and 
desmosomes (Figure 3).  
 
 
Figure 3. Cell-cell and cell-matrix junctions present in epithelial cells. Representation of the main cell-cell 
junctions: tight junctions, adherens junctions, desmosomes and gap junctions. Also, the main actors in cell-matrix 









2.2. Cell-matrix interactions 
 
Cell-matrix interactions are essential for many processes, including normal development, 
migration and proliferation. They are mediated by CAMs, including integrins, selectins, cadherins, 
the Ig superfamily and CD4439. Other actors involved in cell-matrix adhesion are the focal 
adhesions, actin and actin-binding proteins, and scaffolding proteins40.  
 
2.2.1. Extracellular matrix  
 
The extracellular matrix (ECM) is composed of a variable and dynamic network that regulates cell 
behavior and the development and maintains tissue homeostasis. The protein composition of the 
ECM assembles into a three-dimensional structure with specific biochemical and biomechanical 
properties that characterize the cellular microenvironment. Those characteristics determine 
processes like cell growth, survival, motility and differentiation by the interaction with CAMs. 
One important feature of the ECM is that it can be dynamically remodeled and specifically tailored 
to the structure and function of each tissue. Deregulation of the ECM can have serious 
consequences that lead to pathological conditions like cancer. 
Specific matrix components promote tumor progression and metastatic spread41. Some of these 
components, such as fibrillar collagens, fibronectin (FN), hyaluronan and matricellular proteins, 
have been identified as important constituents of the tumor microenvironment and the metastatic 
niche. Additionally, therapeutic resistance has been found related to specific ECM molecules, their 
receptors or enzymatic modifiers42. Amongst the ECM compound, FN plays a role with particular 
interest for this study.  
2.2.2. Fibronectin  
Fibronectin (FN) is an extracellular glycoprotein, synthesized by diverse cell types like fibroblasts, 
smooth muscle cells and endothelial cells43. The proportion of FN in the ECM is variable 
depending on the type of tissue and the conditions of such tissue.  This protein is a dimer of 
subunits. Each monomer has a molecular weight of 250 kDa and is composed of three types of 
modules: FNI, FNII, and FNIII44 (Figure 4). They have binding affinity for some ECM proteins, 
heparin/heparan sulfate moieties, and cell surface integrin receptors43. Binding to integrins is 





Figure 4. Structure of fibronectin chains. Representation of one of the two chains present in the 
dimeric fibronectin molecule, composed for the three modules and the binding sites. From Zipursky, L. B. 
Molecular Cell Biology (2000). 
FN plays a major role in the regulation of many cellular and developmental functions. Some of 
them are cell adhesion, migration, growth, differentiation and proliferation. Also, FN is important 
for processes such as wound healing and embryotic development43.  
Alteration of FN expression has been associated with different pathologies, including multiple 
types of cancer. It has been implicated as one of the main elements in promoting cell survival, 
proliferation, migration, oncogenic transformation and invasion in metastatic models46. For 
example, in breast cancer, FN is expressed to a higher level and with an altered distribution 
compared to normal breast parenchyma46. FN influences cell adhesion and migration because of 
its interaction with integrins and its role as organizer of ECM. 
2.2.3. Focal adhesions 
 
Focal adhesions (FA) are contact points between ECM and cytoskeleton, where integrins 
attach fibronectin or other extracellular matrix compounds to actin filaments inside cells by a 
complex of proteins, such as talins, vinculins, α-actinins and filamins47 (Figure 5). That process 
generates the driving force necessary for cell migration and other processes, such as cell-cell 
contacts.  
Focal adhesion kinase (FAK), part of this protein complex of FA, is a cytoplasmic nonreceptor 
tyrosine kinase essential for the organization of focal contacts and maturation into FA48. FAK can 
be activated (by its phosphorylation) by growth factor receptors or integrins and is a crucial 
mediator their signaling. The overexpression of that kinase has been linked to cancer cell 






Figure 5. Formation of focal adhesion. Integrin-mediated adhesion of fibronectin in the extracellular matrix and 
the actin in the cytoskeleton, through the focal adhesion protein complex. From Variola, F. et al. Nanoscale (2011). 
 
2.3.Cell adhesion in cancer 
 
Multiple and diverse cell adhesion molecules are part of the different steps in cancer progression. 
Alterations in the intercellular and cell-extracellular matrix interactions play a pivotal role in the 
development of invasive and distant metastasis. The metastatic cascade is a complex process where 
cancer cells and other interacting cells have flexible adhesive properties. For example, one of the 
characteristic events is the loss of adhesion between cells at the beginning of the cascade. It results 
in the dissociation of the cell from the primary tumor, degradation of the extracellular matrix and 
acquisition of a motile and invasive phenotype via changes in the cell-matrix interaction and 
composition31. Finally, cells attach with a specific tissue tropism and proliferate at a new location 
to produce the secondary tumor, after extravasation and intravasation processes.  The study of cell 
adhesion and the multiple molecules involved allows their targeting for the development of cancer 












Metastasis refers to the spread of malignant cells to a distant site from a primary cancer location, 
that allows cancer cells to progressively colonize distant organs50. Cancer cells interact with 
metastatic microenvironment to alter antitumor immunity and the extracellular microenvironment. 
This is often associated with genomic instability, survival signaling, chemotherapeutic resistance 
and proliferative cycles51. 
Metastasis also has organ specificity. Different types of cancer have characteristic tendencies to 
metastasize to particular sites.  Additionally, it depends upon properties of the host as well as 
alterations in the cancer cells52. This metastatic process follows three different routes.  The first is 
lymphatic metastasis, which involves colonization of the regional lymph nodes. The second is 
travel via open cavities such as the pleural cavity or abdominal cavity (peritoneal metastasis). The 
third is travel through the bloodstream or hematogenous metastasis52. 
Metastasis is a major contributor to the deaths of cancer patients. Therefore, prevention of the 
initiation of metastasis in high-risk patients is a major therapeutic objective2.  
3.1. Metastasis in breast cancer 
The majority of deaths from breast cancer are not due to the primary tumor as the main cause, but 
are the result of metastases to other organs in the body. Among women diagnosed with breast 
cancer, only a minority is classified with stage IV disease, which is nearly always incurable. It 
happens when some patients initially present with distant metastasis or other patients without 
detectable metastasis at the time of diagnosis. However, around 30% of the patients initially 
diagnosed with an early-stage disease will develop metastatic lesions within months or even years 
later53.  
The development of breast cancer involves a progression through a series of intermediate 
processes, starting with ductal hyperproliferation, followed by subsequent evolution to carcinoma 
in situ, invasive carcinoma, and finally into metastatic disease54. Breast cancer metastasis is the 
result of the interplay between cancer cells and the surrounding microenvironment, which is 
regulated by complex molecular networks and involved numerous genes. Currently, two processes 
that have a main role into the metastatic cascade have been pinpointed as a focus of 
investigation: epithelial-mesenchymal transition (EMT) and tumor microenvironment interactions 
where cell adhesion molecules play a major role. 
3.2. Metastatic cascade  
The metastatic cascade is a complex process, that comprises a series of sequential steps. This 
process is considered highly inefficient, a failure to complete any of these steps will arrest the 
process. However, because of the high mortality associated with metastasis, the metastatic cascade 
has been under intense investigation in hopes to eliminate distant spread and reduce their cancer‐
associated mortality55. 
During carcinoma metastasis, stationary epithelium‐derived cancer cells must first become 




cancer cells are disseminated into the bloodstream or lymphatic vessels to distant organs56. Upon 
surviving the transport, some circulating tumor cells (CTCs) undergo cell cycle arrest and adhere 
to capillary beds within the target organ. After, they manage to extravasate out of the vasculature 
into the organ parenchyma, proliferating and promoting angiogenesis within the organ and initiate 
distant metastasis colonization. Simultaneously to these steps, the cancer cells must evade the 
host’s immune response and apoptotic signals (anoikis) in order to survive57. At distant sites, 
disseminated cancer cells need to adapt to the new microenvironment and create a metastatic 
supportive niche, and switch back from the migratory mode to proliferation mode to repeat the 
process to produce secondary metastases55 (Figure 6). 
3.2.1. Invasion  
Metastasis begins with the invasion of cancer cells into the surrounding host tissue. Degradation 
of the ECM allows the penetration into tissue boundaries, following by invasion. The cell-to-cell 
adhesion and cell-ECM adhesion are also altered by the invasive cancer cells58. For example, the 
cadherin family plays a predominant role in breast cancer metastasis. The down-regulation of E-
cadherin, which maintains cell-cell junctions, is a determinant in the outgrowth of metastatic breast 
cancer cells and reflects its progression and metastasis associated with poor prognosis.  Epithelial-
mesenchymal transition (EMT) plays a major role in tumor progression by assisting invasion and 
intravasation into the bloodstream or lymphatic vessels, and inducing proteases involved in the 
degradation of the ECM. As markers of the process are E-cadherin and N-cadherin. First, the 
down-regulation of E-cadherin results in the loss of cell-cell adhesion between epithelial breast 
cancer. Second, the increase in N-cadherin or other mesenchymal cadherins, enables the adhesion 
of cancer cells to stromal cells, promoting the invasion of cancer cells into the stroma34. 
Additionally, some mutations in E-cadherin which lead to its functional loss were discovered in 
lobular breast carcinoma. In some systems, host cells such as macrophages, fibroblasts and the 
coagulation system are required for efficient invasion and metastasis59. 
3.2.2. Migration and mobility  
Cancer cells need to migrate from the primary site in order to achieve an invasive phenotype. 
Those cells are able to migrate either singly or coordinately60. Primary, cancer cells that migrate 
collectively need the presence of intercellular junctions and after invasion and intravasation, they 
commonly circulate as emboli in the blood or lymphatic vessels. On the other hand, single cancer 
cells migrate in two ways, mainly by protease-dependent mesenchymal movement, where EMT is 
a critical pathway, or via the protease-independent amoeboid movement26. For being able to leave 
the primary tumor and invade the surrounding tissue, cancer cells need to reduce their cell-cell 
adhesion. This action allows disaggregation of cancer cells from the primary site to initiate 








Figure 6. The metastatic cascade. Metastasis is a process that occurs in two major phases: (i) physical 
translocation of cancer cells from the primary tumor to a distant organ and (ii) colonization of the translocated cells 
within that organ. (A) Cancer cells acquire a invasive phenotype to begin the metastatic cascade, (B) Cancer cells 
invade into the surrounding matrix, and then they intravasate to enter into blood vessels (C) Circulating tumor cells 
(CTCs) travel through the circulation to distant organ. They display properties of anchorage-independent survival. 
(D) At the distant organ, CTCs extravasate and invade into the microenvironment of the foreign tissue. (E) At that 
foreign site, cancer cells must be able to survive, evading the innate immune response as a single cell (or as a small 
cluster of cells). (F) Cancers cell must be able to adapt to the microenvironment and initiate proliferation. From 
Chaffer and Weinberg, Science (2011). 
3.3. Epithelial-mesenchymal transition  
Two of the main cell types in mammals are epithelial and mesenchymal cells. Epithelial cells are 
characterized by cohesive interactions among cells that facilitate the formation of continuous cell 
layers, presenting three membrane domains (apical, lateral and basal), tight junctions between 
apical and lateral domains, apicobasal polarized distribution of the various organelles and 
cytoskeleton components and a lack of mobility of individual epithelial cells with respect to their 
local environment. On the other hand, multicellular mesenchymal architectures are characterized 
by loose or no interactions among cells - so that no continuous cell layer is formed - no clear apical 
and lateral membranes, no apicobasal polarized distribution of organelles and cytoskeleton 
components and motile cells that may even have invasive properties62.  
 
Some cells can switch from an epithelial to a mesenchymal status by a regulated process defined 
as the epithelial to mesenchymal transition (EMT), which is a highly complex and dynamic 
process with numerous overlapping pathways, cellular and molecular events. The EMT program 
is a spectrum of cell states in transition, where epithelial cells could undergo a partial EMT and 
present a partial epithelial and mesenchymal characteristics55. In some cases, EMT is reversible 







Figure 7. Cycle of events during EMT (epithelial–mesenchymal transition) and the reverse process MET 
(mesenchymal–epithelial transition). The different stages during EMT and MET are regulated by effectors of 
EMT and MET, which influence each other. Important events during the progression of EMT and MET, including 
the regulation of the tight junctions and the adherens junctions, are indicated. Additionally, a number of markers 
that have been identified as characteristics of either epithelial or mesenchymal cells and these markers. E-cadherin, 
epithelial cadherin; ECM, extracellular matrix; FGFR2, fibroblast-growth-factor receptor-2; FSP1, fibroblast-
specific protein-1; MFs, microfilaments. Adapted from Thiery and Sleeman, Nature Reviews (2006). 
EMT was originally described as an integral part of morphogenesis in embryonic development and 
later was observed in several pathogenesis events, including wound healing, fibrosis and cancer 
metastasis55. It is associated with tumorigenesis, invasion, metastasis, tumor stemness and 
resistance to therapy46. During the EMT process, cells lose their epithelial characteristics and 
acquire mesenchymal features, which enable them to migrate more efficiently and invade the 
underlying mesenchyme. 
EMT starts with the disintegration of cell-cell adhesion by losing epithelial markers, such as E-
cadherin, and expressing mesenchymal markers, such as N‐cadherin, fibronectin and vimentin, in 
order to leave the primary tumor site and invade the surrounding tissue.  Therefore, the expression 
of transcriptional repressors of E-cadherin is associated with poor prognosis in breast carcinoma64. 
Some of them include zinc finger E-box-binding homeobox 1 (ZEB1), zinc finger E-box-binding 
homeobox 2 (ZEB2), twist-related protein (Twist), zinc finger protein, Snail and Slug. There are 
involved in signaling pathways such as transforming growth factor-β (TGF-β), the wingless-type 
MMTV integration site family, (WNT) cascade and the phosphatidylinositol 3’ kinase-
serine/threonine kinase (PI3K/AKT) axis, all linked to the EMT programs (Figure 8)62. Following 




is altered from apical-basal polarity to front-rear polarity to initiate cell migration through 
reorganization in cortical actin and actin stress fibers, that induces cytoskeleton remodeling. 
Finally, increased cell protrusions and expression of metalloproteinases (MMPs) result in ECM 
degradation, cell migration and invasive behavior55. 
After all these processes, these cells are loosely attached to the ECM, lose cell polarity and move 
through the paths of least resistance. Some of these cells, which have undergone EMT, have an 
elongated fibroblast-like shape and their movement is facilitated by matrix-degrading enzymes, 
such as MMPs, which are released through channels in the ECM. Contrarily, cells with amoeboid 
movement are round cells like unicellular organisms. The last ones rely mostly on shape 
deformations and structural changes in the ECM composition rather than actual degradation of the 
matrix. Also, that modification in the ECM composition depends on the cell phenotype. Some of 
those modifications help the cell migration; for example, the increase in fibronectin (FN) type III 
expression for amoeboid and FN type I expression for migrating cells.  The mechanical force used 
is generated by active myosin/actin contractions and cortical actin via signaling pathways such as 
RhoA/Rho kinase (ROCK)63. 
 
Figure 8. Signal transduction pathways associated with epithelial–mesenchymal transition. End points of 
EMT are boxed. RTK: receptor tyrosine kinase; ROS: reactive oxygen species. From Larue and Bellacosa, 
Oncogene (2005). 
3.4. Tumor microenvironment  
The tumor microenvironment appears to play a role in metastatic potential and is critical for 
cancer cell proliferation. An appropriate microenvironment is a requirement for establishing tumor 




immune cells - such as fibroblast, macrophages, natural killer cells, endothelial cells - together 
with all types of tumor cells, the ECM, and the lymphatic and vascular systems65 create the 
microenvironment that supports tumor progression59 (Figure 9).  
The cell-matrix and cell-cell interactions into this microenvironment imply a number of specific 
cell surface-associated molecules, including the family of integrin receptors, the cadherins, the 
immunoglobulin (IgG) superfamily, a 67-kDa laminin-binding protein, and the CD44 receptor, 
that interact with hyaluronic acid and also with other ligands, such as osteopontin, collagens and 
MMPs44. Those interactions also affect the metastatic potential and build the way for the 
progression from in situ cancer to metastatic cancer.  
The migratory and invasive abilities are the crucial parameters of cancer cells, as well as the 
interaction with the ECM61. Those adhesion receptors of the cancer cell surface play an important 
role in one of the earlier steps of metastasis, the migration of cells through the basement membrane 
and ECM surrounding the tumor. 
Cancer cells secrete substances prior to metastasis to establish a pre-metastatic niche supporting 
future metastatic sites. These signals from the primary tumor also could determine and promote 
preferential invasion of cancer cells to a particular site. Indeed, breast cancer has been observed to 
preferentially metastasize to the bone and lungs and less frequently to other organs such as the 
liver and brain. Gene expression signatures accounting for the preferential metastasis of breast 
cancer cells to the bone marrow and lung have been identified, providing evidence that metastasis 
exhibits tissue tropism66.  
Angiogenesis is another important aspect in metastasis, establishing tumor vasculature and 
subsequent metastasis growth. Genetic mutations, mechanical stresses, inflammatory processes, 
tumor expression of angiogenic proteins and hypoxia are believed to cause the angiogenic process, 








Figure 9. The microenvironment supports metastatic dissemination and colonization at secondary sites. 
Some cells such as macrophages, platelets, and mesenchymal stem cells (MSCs) contribute to EMT at primary 
sites, allowing for cancer cells to separate from neighboring epithelial cell-cell contacts and acquire a 
mobile/invasive phenotype. One major mediator of this event is TGF-β. Tumor-associated macrophages (TAMs), 
cancer-associated fibroblasts (CAFs) and myeloid progenitor cells also tend to cluster at the invasive/leading edge 
of the primary tumor, where they play an immunosuppressive role by interfering with dendritic cell differentiation. 
Macrophages help during the intravasation of cancer cells into circulation. In the circulation, platelets and 
components of the coagulation system support cancer cell survival by protecting them from cytotoxic immune cell 
recognition. At secondary sites such as the lung, fibroblasts upregulate fibronectin, which serves to the arrival of 
cancer cells. Immunosuppressive cell types also populate premetastatic niches where they help to direct metastatic 
dissemination by creating a niche permissive to tumor colonization. Factors contained in exosomes have the 
capacity to direct organ tropism, modulate immune evasion, support mesenchymal-to-epithelial transition (MET), 











4. Integrins in cancer progression and metastasis  
Integrins are expressed on epithelial cells and because many tumors originate from epithelial cells, 
they are also expressed in cancer cells30. Additionally, integrin are the main cellular adhesion 
receptor and they have multifaceted roles and implication in cell migration. These characteristics 
implicate them in almost every step of cancer progression and metastasis, as it is illustrated in 
Figure 10.  
Nevertheless, due to the complexity of integrins, their study in order to find new therapeutic targets 
or diagnosis predictor has been a challenge.  First, they have adaptable and even antagonist roles 
in cancer cells and tumor microenvironment. Another interesting characteristic is that some 
integrins can interact with just one specific ECM ligand, such as fibronectin, vitronectin, laminin, 
or collagen; but others can bind to multiple ligands. It is for example the case for the integrins of 
interest for this study, ITGA5 that binds specifically to FN. Moreover, the interaction of different 
integrin heterodimers with the same ligand can trigger a totally different signaling in the cell. 
Because of that, integrin expression on the cell surface is key to determining cell response to 
microenvironmental influences37. 
Studies correlate integrin expression levels in cancer cells with metastatic progression in many 
types of cancer like melanoma, breast carcinoma, prostate and pancreatic and lung cancer. Some 
of the integrins identified with those pathological outcomes are αvβ3, αvβ5, α5β1, α6β436.  
For example, one of the α integrins, αv, dimerizes with the specific β integrin subunits has been 
implicated in the pathophysiology of malignant tumors (Figure 2)68. Especially, integrin αvβ3 has 
been coupled to EMT and metastasis, induced cancer cell migration, and for maintaining a 
mesenchymal phenotype of these cells69. Interactions with the ECM through integrin 
adhesion receptors provide cancer cells with physical and chemical signals that act together with 
growth factors to support survival and proliferation44. The major adhesion receptor for FN is α5β1 
integrin, implying a relationship between the expression of the integrin and tumor metastasis. 
Moreover, some of these studies are contradictory in the information about the same type of cancer 
or the role of the same integrin in different cancer types37. For this reason, the mechanism by which 







Figure 10. Integrins involved in different steps of cancer progression. Integrin expression have been implicated 
in the different stages of cancer development and metastasis (parts a-d). Also, they have been related to the 
acquisition of drug resistance (part e). Because all of that, integrins are considered attractive as new therapeutic 









5. PACMAN Project 
The different pathways implied in cell migration and invasion are in continuous study. How they 
are related to cancer progression and metastasis still unclear, as well as the role of integrins in 
those processes. One of the challenges is the difficulty of isolate non-migrating cells from 
migrating cells present within the same sample, in a way to analyze their gene expression and to 
identify the pathways involved in metastasis formation. Additionally, recreate the complexity of 
the complete tumor microenvironment in vitro is another challenging task. 
The PACMAN (Peptide-Assisted Cellular Migration Along eNgineered surfaces) project is a 
research project that through PACMAN surfaces aims to separate MDA-MB-231 cells regarding 
their migrating phenotype (Figure 11). The static and the different migratory phenotypes are 
characterized and compared in a way to identify pathways involved in the metastatic process. 
To this aim, this project focusses on ECM composition and particularly on the role of FN motifs 
in distal migration in breast cancer model, and more particularly on the role of integrins ITGA5 
and ITGB3. These integrins can be extrinsically activated by a highly conserved sequence of FN 
type I (IGDQ motif) or intrinsically by the activation of the EGFR pathway.  
Previous results from our laboratory, obtained in the PACMAN project, showed that IGDQ-
exposing (Iso-Gly-Asp type I FN motif) monolayers (SAMs) sustain the adhesion of MDA-MB-
231 cells, a metastatic breast cancer cell line, by triggering FAK, similarly to the analogous RGD-
terminating (Arg-Gly-Asp type III FN motif) surfaces70, with migrating cells at the cm-subscale 
for IGD and only proliferation for RGD. Further analysis of these ECM proteins and the 
downstream ECM mediated signaling pathways may provide a range of possibilities to identify 
therapeutic/diagnostic targets against advanced breast cancer. 
 
Figure 11. Breast cancer cells migrating on PACMAN IGDQ-exposing surface.  Modified from V. Corvaglia 















Although the importance of breast cancer has been recognized due to its high incidence in women 
around the world, and the metastatic process has been widely studied in order to prevent and treat 
this disease; metastasis is still the leading cause of breast cancer mortality. For this reason, it is 
important to understand the relationship between cancer cells and the surrounding 
microenvironment, which is regulated by complex molecular networks and involving numerous 
genes amongst which are integrins. 
The purpose of this study was to characterize the role of ITGA5 and ITGB3 in cell migration using 
an in vitro model of metastatic breast cancer. Given that matrix components and many 
ECM proteins, such as FN, promote tumor progression and metastatic spread, and that integrins 
are cell-surface adhesion receptors that interact with ECM components and have been reported to 
contribute to tumor growth, cell adhesion, invasion, and metastasis.  
We chose to use MDA-MB-231 cells because they are originating from one metastasis of a triple-
negative breast cancer. 
<sup>38</sup>This thesis is part of Sophie Ayama’s work that aims to characterize and compare 
the different phenotypes of MDA-MB-231 cells regarding their migration in order to identify 
pathways involved in cell migration. A special focus is put on integrins α5β1 and αvβ3, using 
PACMAN surfaces and single cell deep RNA sequencing. 
The first part of this project consisted in invalidating the expression of ITGA5 or ITGB3 using 
siRNA. Additionally, ITGA5 was invalidated using shRNA in order to allow a stable and long-
term invalidation of the target gene. To assess the effectiveness of this invalidation, mRNA and 
protein expression levels were analyzed by RT-qPCR and by western blotting and 
immunofluorescence labeling, respectively.  Characterization of control and invalidated cells were 
performed by morphological observations. Also, cytotoxicity was evaluated. Finally, cell 
migratory capacity was assessed to determine the role of the integrins in cell migration.  
For the second part of the thesis, other ITG-targeting shRNA were tested, and invalidated cells 
were characterized with the same methods. In addition, cell adhesion capacity was evaluated. 
Furthermore, a co-invalidation of ITGA5 and ITGB3 was performed and its importance on 
migratory capacity was evaluated. 
The results highlighted that integrins influence some of the features of metastatic breast cancer 
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1. Cell culture  
1.1. Cellular model 
The model used during this thesis is the MDA-MB-231 cell line (ATCC® HTB-26™) (ATCC, 
USA). It is a human breast cancer cell line, derived from the pleural effusion of a metastatic site. 
They are mesenchymal-like epithelial adherent cells that express epidermal growth factor (EGF) 
and transforming growth factor alpha (TGF alpha).  
1.2. Culture conditions 
MDA-MB-231 cells were cultured in 75 cm² polystyrene cell culture flasks (T75) (Corning, USA) 
containing 15 mL of RPMI-1640 medium (Gibco, USA) supplemented with 10% fetal bovine 
serum (FBS) (Gibco, USA). Cells were maintained under standard culture conditions in a 
humidified 5% CO² atmosphere at 37 °C.  
MDA-MB-231 cells were subcultured every 2 to 3 days according to the following protocol: the 
culture medium was removed from the flask and cells were rinsed with 10 mL of homemade sterile 
phosphate buffer saline (PBS) (Table 1) to remove all traces of serum. After discarding the PBS, 
cells were detached using 1.5 mL 0.05% trypsin-EDTA (Gibco, USA) for 5 minutes at 37 °C. 
After cell detachment, cells were recovered with 8.5 mL of complete medium in order to inhibit 
the trypsin via the protease inhibitors contained in the serum and then placed in a 15 mL centrifuge 
tube (Sigma-Aldrich, USA). The tube was centrifuged for 5 minutes at 1000 rpm to pellet the cells. 
Next, the supernatant was discarded, and the cell pellet was resuspended with 5 mL of media which 
were then divided into one or more T75 flasks. Finally, fresh medium was added to obtain a final 
volume of 15 mL and the flasks were replaced into the CO₂ incubator.  
Table 1. Phosphate buffer saline (PBS) homemade: preparation for 1 L. 
Reagent Quantity 
Phosphate buffer KH₂PO₄ 0.5 mM at pH 7.4 (Merck, 
Germany) 
20 mL 
NaCl 99% (Carl Roth, Germany) 9 g 
 
1.3. Cell counting 
After the centrifugation step for 5 minutes at 1000 rpm to pellet the cells, the supernatant was 
discarded, and the cell pellet was resuspended with RPMI-1640-10% FBS medium in a 15 mL 
centrifuge tube. 10 μL of the sample were added to 10 μL of trypan blue stain 0.4% (NanoEntek, 
Korea) and mixed gently by pipetting up and down. Then 10 μL of the sample mixture were added 
to the chamber ports on one side of the Countess™ cell counting chamber slides (Invitrogen, 
USA). The slide was inserted into the slide inlet on the Countess™ automated cell counter 
(Invitrogen, USA), the parameters were set and the instrument counted cells in each sample. The 
number of living cells and the percentage of survival were recorded. 
2. siRNA knockdown  
The previous day of the transfection, MDA-MB-231 cells were seeded in 25 cm2 polystyrene cell 
culture flasks (T25) (Corning, USA) at a density of 700 000 cells per flask in 5 mL RPMI-1640 
medium (Gibco, USA) supplemented with 10% FBS (Gibco, USA). The flasks were incubated at 
37 °C in a humidified 5% CO₂ atmosphere.  
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SMART-Pool-ON-TARGET human single siRNAs were purchased from Dharmacon and the final 
siRNA concentration was 50 nM per sample (siRiscFree (siRF), ITGB3-targeting siRNA (siB3), 
ITGA5-targeting siRNA (siA5)). As negative controls, siRF and untransfected cells (UT) were 
used. After 24 hours of incubation, cells were transfected in duplicate with siRNA DharmaFECT 
transfection reagent (Dharmacon, USA). First, in separate tubes, 10 μL of the siRNA was diluted 
(Tube 1) in 390 μL of serum-free medium Opti-MEM (Gibco, USA) and 8 μL of the appropriate 
DharmaFECT transfection reagent (Tube 2) with 392 μL of the same serum-free medium. Second, 
the content of the tubes was gently mixed by pipetting carefully up and down and incubated for 5 
minutes at room temperature. Third, the content of the tube 1 was added to the tube 2, mixed by 
pipetting and incubated for 20 minutes at room temperature. Finally, the culture medium was 
removed from the flasks and the siRNA mix was added into RPMI-1640-10% FBS medium to 
achieve a volume of 4 mL.  
After cells were incubated 24 hours at 37 °C in 5% CO₂, the medium was replaced by complete 
medium RPMI-10% FBS. Gene silencing efficiency was determined by RT-qPCR and Western 
blot analysis. 
3. shRNA knockdown 
3.1. Bacterial culture and plasmid purification 
The bacterial amplification was performed with transformed MISSION shRNA bacterial glycerol 
stocks (Sigma-Aldrich, USA). The plasmids contained the SHC001 expression vector for the 
integrin α5 shRNA 126 or shRNA 124, or integrin β3 shRNA 236 or shRNA 237, sequences with 
ampicillin resistance marker for prokaryote selection.  A 15 mL centrifuge tube (Sigma-Aldrich, 
USA) was prepared for each treatment with 5 mL of sterilized LB medium, 20 µL of the bacteria 
in glycerol stock and 5 µL of ampicillin 50 mg/mL (Roche, Germany). The solution was incubated 
for 8 h at 37 °C on a shaker at 125 rpm. After that, for each sample in a 500 mL Erlenmeyer were 
added 125 mL of LB medium, 125 µL of ampicillin 50 mg/mL and the content in the first pre-
amplified bacterial tube. They were incubated for 24 h at 37 °C, 125 rpm.  
Afterward, the plasmids were purified using the Plasmid Plus Maxi kit (Qiagen, Germany) 
following the protocol for high-copy plasmid, according to the manufacturer’s instructions. The 
quality and the quantity of the plasmids were determined by Nanodrop spectrophotometer N-100 
(Isogen Life Science, The Netherlands) by measuring the absorbance at 260 nm. And then the 
samples were kept at -20 °C. 
3.2. Lentiviral particle production  
Lentivirus-based vector expressing integrin α5 shRNA 126 or shRNA 124 sequence was generated 
by transient co-transfection of HEK293T cells with a plasmid encoding the gag, pol, rev, and 
envelope genes and 2X hepes buffered saline (HeBS), adjusted to pH 7.05 and 7.12. HEK293T 
cells were seeded one day before the transfection in 75 cm² polystyrene cell culture flasks (T75) 
(Corning, USA) at a density of 1 million cells per flask. Briefly, a T75 flask of non-confluent (40-
60%) cells were transfected with 3.34 μg of Δ8.3(pol), 1.67 μg of VSV-G (env) and 5 μg of 
lentiviral vector plasmid mixed with the diluent (720 μL ddH2O, 110 μL CaCl2 2.5 M). 840 μL 
HeBS 2X (Table 2) were added dropwise to the mix, vortexed immediately and incubated at room 
temperature (RT) for 20 min. Following the incubation, the mixture was added to partially 
confluent HEK 293T cells with DMEM medium (Gibco, USA) supplemented with 10% FBS 
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(Gibco, USA) and glutamine. The medium was changed 24h post-transfection. 48 h post-
transfection, lentivirus-containing supernatant was harvested and used for the following 
experiments. 
Table 2 HeBS homemade: preparation for 500mL. 
Reagent Quantity 
NaCl 274 mM 8g 
KCl 10 mM 0.37g 
Na2 HPO4.2H2O 1.5mM 0.1065g 
Dextrose (glucose) 1g 
Hepes 50mM 5g 
 
3.3. shRNA transduction  
MDA-MB-231 cells were seeded the previous day of the transduction in 25 cm2 polystyrene cell 
culture flasks (T25) (Corning, USA) at a density of 300 000 cells per flask. Cells were transduced 
with shRNA targeting integrin α5 (sh126 or sh124) or integrin β3 (sh236 and sh237) with shRNA 
lentiviral particles produced in HEK293T cells. The transduction was performed for each lentivirus 
at two different dilutions (12 and 1/5) in fresh RPMI-1640 medium (Gibco, USA) supplemented 
with 10% FBS (Gibco, USA) containing protamine sulfate (60 µL/flask) (Sigma-Aldrich, USA) 
as the transducing agent.  Two different controls were performed, untransduced cells and shRNA 
Ctrl cells, the latter were transduced with lentiviral particles Empty Vector (Sigma-Aldrich, USA) 
with a multiplicity of infection (MOI- number of particles per cell) of 5 in the same conditions of 
fresh medium containing protamine sulfate (0.06 mg/mL).  48 hours after the transduction, the 
medium was replaced by fresh medium supplemented with puromycin (2 μg/mL) (Sigma-Aldrich, 
USA) to select cells that were infected by the lentiviral particles and having incorporated the vector 
into their genome. The selection was maintained from 5 to 6 days while the cells were amplified 
in 75 cm2 polystyrene cell culture flasks (Corning, USA). After the selection, a dilution ½ was 
chosen for further experiments and cells were frozen in RPMI-1640-10% FBS medium– 5% 
dimethylsulfoxid (DMSO) (Carl Roth, Germany) in liquid nitrogen.  
4. Immunofluorescence labeling 
Cells were seeded on sterile glass coverslips (Glaswarenfabrik Karl Hecht KG, Germany) in 24-
well plates (Costar, USA) at a density of 30 000 cells per well in RPMI-1640 medium (Gibco, 
USA) supplemented with 10% FBS (Gibco, USA). First, after 48 hours of incubation at 37 °C in 
5% CO₂, the medium was removed, and cells were fixed during 10 minutes at RT with PBS-PFA 
4% (paraformaldehyde) (PFA 0.04 g/mL (Merck, Germany) in PBS non-sterile (Table 1) before 
being washed 3 times with PBS. Second, cells were permeabilized with PBS-Triton X 100 1% 
(Triton X-100 0.01 g/mL (Carl Roth, Germany) in PBS non-sterile) for 5 minutes at RT, followed 
by 3 washes for 10 minutes each with PBS-BSA 2% (bovine serum albumin) (VWR, USA).  Third, 
the cells were incubated with the primary antibody overnight at 4°C (Table 1) in the dark and in a 
humid chamber. The next day, cells were rinsed 3 times for 10 minutes each with PBS-BSA 2% 
and incubated for 1 hour with the secondary antibody and/or probe (Table 3) and simultaneously 
with the Hoechst #H-21491 (Thermo Fisher Scientific, USA) diluted at 2 μg/mL PBS-BSA 2% at 
RT in the dark. Afterward, cells were washed 2 times with PBS-BSA 2% and 2 times with PBS. 
Finally, the coverslips were mounted on microscope slides (VWR, USA) with Mowiol mounting 
solution (Sigma-Aldrich, USA) prewarmed at 56°C. Slides were kept at 4°C protected from light 
Material and methods 
24 
 
before the observation with the confocal laser scanning fluorescence microscope TCS SP5 (Leica, 
Germany).  
Samples obtained after the immunofluorescence labeling were scanned by confocal microscope 
TCS SP5 (Leica, Germany) to obtain z-series image stacks to determine the cell size on the z-axis, 
in order to analyze cell adhesion.   
Table 3 Antibodies used for immunofluorescence labeling. 
Protein Primary antibody Secondary antibody 
Integrin α5 
 
Anti-integrin alpha 5  
Rabbit, 1/100 
(Abcam, UK) 
Alexa 488 nm 
Anti-rabbit, A-11008, 1/1000 
(Thermo Fisher Scientific, USA) 
Integrin β3 Anti-integrin beta 3  
Mouse, 1/50 
(BD Biosciences, USA) 
Alexa 568 nm 
Anti-mouse, A-11004, 1/1000 
(Thermo Fisher Scientific, USA) 
pFAK Anti-pFAK 
Mouse, 1/100 
(BD Biosciences, USA) 
Alexa 568 nm 
Anti-mouse, A-11004, 1/1000 
(Thermo Fisher Scientific, USA) 
Phalloidin probe 
(F-actin) 
 Alexa fluor Phalloidin 568 nm 
A-12380, 1/100 
(Thermo Fisher Scientific, USA) 
 
5. Total RNA extraction and RT-qPCR 
5.1. Total RNA extraction 
Cells were seeded in 25 cm2 polystyrene cell culture flasks (T75) (Corning, USA) at a density of 
400 000 cells per flask and incubated for 48 hours at 37°C with 5% CO2 in a humidified 
atmosphere. Then, the medium was discarded, cells were scraped in 600 μL of PBS (Table 1) and 
collected in a 1.5 mL Eppendorf (Qiagen, Germany). Afterwards, the tube was centrifuged for 5 
min at 1200 RPM and 4°C. The supernatant was removed and 600 μL of RLT Lysis Buffer of the 
RNeasy Mini Kit (Qiagen, Germany) were added to lyse the cells in a 2 mL Eppendorf (Qiagen, 
Germany). Total RNA was then extracted using the RNeasy Mini Kit and the automate QIAcube 
(Qiagen, Germany) under conditions “Large sample with DNase” with an elution volume of 30 
μL. The samples were kept at -80°C. Total RNA concentration was quantified using Nanodrop 
spectrophotometer N-100 (Isogen Life Science, Netherlands) by measuring the absorbance at 260 
nm. 
5.2. Retro-transcription of mRNA into cDNA 
The retro-transcription of the mRNA to cDNA was performed using the GoScript reverse 
transcription kit (Promega, USA). 1 μg of total RNA was diluted with RNase-free water to a 
volume of 12 μL. The samples were then incubated at 70 °C for 5 minutes. A reaction mixture of 
8 μL containing 4 μL of GoScript buffer mix with random primers (Promega, USA), 2 μL of 
GoScript enzyme mix (Promega, USA) and 2 μL of nuclease-free water was added to each sample 
to obtain a final volume of 20 μL. The samples underwent a thermal cycle of 5 minutes at 25 °C, 
then 60 minutes at 42 °C and finally, 15 minutes at 70 °C. The cDNA sample tubes obtained were 
directly placed on ice and stored at -20 °C. 
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5.3. Real time PCR 
In a qPCR 96-well reaction plate (Thermo Fisher Scientific, USA) were added 4 μL of cDNA 
diluted at 1/100 and 16 μL of the reaction mix per well. This qPCR mix was prepared with 5.56 
μL of MilliQ water, 0.22 μL of each forward and reverse primers (Integrated DNA Technologies, 
USA) to 300 nM (Table 4) and 10 μL GoTaq® qPCR Master Mix (Promega USA). After the wells 
were filled, the plate was sealed and centrifuged for 1 minute at 600 rpm.  
The amplification was quantified using the threshold cycle (Ct) method using ViiA 7 Real-Time 
PCR System (Thermo Fisher Scientific, USA). Thermal cycling conditions were composed of an 
initial denaturation step at 95°C for 5 min, followed by 40 cycles at 95°C for 30 seconds and 60°C 
for 1 min. 
Gene expression was determined using the ΔΔCt method with tubulin as the housekeeping or 
reference gene. For each sample, the Ct of the reference gene is subtracted from the Ct of the gene 
of interest in order to normalize the amount of cDNA loaded into each well: 
ΔCt = Ct gene of interest - Ct reference gene 
ΔΔCt = ΔCt of the gene in a condition - ΔCt of the gene in the control condition 
2−ΔΔCt = level of induction or repression of the gene in comparison to the control condition 
Table 4 Primers used for qPCR. 
Gen Primer Sequence %GC Tm °C Amplicon size (bp) 
ITGB3 ITGB3-F-h CCGTGACGAGATTGAGTCA 52.63 56.91 132 
 
ITGB3-R-h AGGATGGACTTTCCACTAGAA 42.86 55.69 
 
ITGA5 ITGA5-F-h TGCAGTGTGAGGCTGTGTACA 52.38 61.91 88 
 
ITGA5-R-h GTGGCCACCTGACGCTCT 66.67 62.01 
 
Α-Tubulin Tub-178F CCCGAGGGCACTACACCAT 63.16 60 108 
 Tub-323R CAGGGAGGTGAACCCAGAAC 60 60  
 
6. Protein extraction and Western blotting 
6.1. Protein extraction 
Cells were seeded in 25 cm2 polystyrene cell culture flasks (T75) (Corning, USA) at a density of 
400 000 cells per flask and incubated for 48 hours at 37°C with 5% CO2 in a humidified 
atmosphere. Then, the medium was discarded, cells were scraped in 600 μL of PBS (Table 1) and 
collected in a 1.5 mL Eppendorf (Qiagen, Germany). Afterwards the tube was centrifuged for 5 
min at 1200 RPM and 4°C. The supernatant was removed and the cell pellet was resuspended in 
30 μL of lysis buffer solution (Table 5). After being incubated 15 min on ice, the sample was 
sonicated for 10 seconds 3 times and stored at -80°C.  
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Table 5 Reagents of lysis buffer solution 
PIC (Phosphatase Inhibitor 
Cocktail) 
A tablet of Complete protease inhibitor cocktail 25X 
(Roche, Germany) dissolved in 2 mL of water 
PIB (Phosphatase Inhibitor 
Buffer) 
- Na₃VO₄ 25 mM (Sigma-Aldrich, USA) 
- PNPP (Para-NitroPhényl Phosphate) 250 mM 
(Sigma-Aldrich, USA) 
- β-glycerophosphate 250 mM (Sigma-Aldrich, 
USA) 
- NaF 125 nM (Merck, Germany) 
Lysis buffer stock - 929 mg of Tris (Trizma Base) 40 mM (ICN 
Biomedicals, USA) 
- 2.23 g of KCl 150 mM (Merck, Germany) 
- 74.44 mg d’EDTA (Tritriplex III) 2 mM (Merck, 
Germany) 
Lysis buffer - 1 mL of lysis buffer stock 
- 2 μL of β-mercaptoethanol 
- 40 μL of PIC 
- 40 μL of PIB 
 
6.2. Determination of protein concentration 
Quantification of proteins was carried out using Pierce 660 nm Protein assay (Thermo Fisher 
Scientific, USA), that allows assessing the protein concentration of a sample through a colorimetric 
analysis where the absorbance of the samples is measured spectrophotometrically at 660 nm. 
To determine the protein concentration as a function of the absorbance, a calibration curve was 
performed obtaining the absorbance of different concentrations of BSA (stock at 2 μg/μL ) (Sigma-
Aldrich, USA) diluted in water. 10 μL of each diluted sample (1 μL of sample + 9 μL of water) 
were placed in a 96-wells plate (Costar, USA), as the blank of lysis buffer, in order to be able to 
subtract its absorbance from the absorbance of the samples. 150 μL of Pierce solution was added 
to each well and the plate was then placed in the dark between 5 to 20 minutes. Absorbance was 
measured at 660 nm using a spectrophotometer (Bio-Rad, USA) to calculate the protein 
concentration of the samples based on the equation of the calibration curve (y = ax + b) with y 
representing the absorbance and x the protein concentration. 
6.3. Gel electrophoresis  
Proteins were separated using a 10% homemade polyacrylamide gel. First, the 10% separation gel 
(running gel) was poured and a thin layer of SDS 0.1% was added to isolate the gel from oxygen 
and promote polymerization. Second, after 40 minutes of polymerization at RT, the gel was rinsed 
with milliQ water. Then, the 4% concentration gel (stacking gel) was poured, a comb comprising 
10 or 15 wells was inserted and the gel polymerized for 30 minutes (Table 6). 
For each sample, 7 µg of proteins from cell lysates were mixed with MilliQ water and 6 μL of 
loading blue 5X (Table 6) to achieve a final volume of 30 μL. The samples were heated for 5 
minutes at 100 °C and then span briefly. 
30 μL of sample or 2 μL of molecular-weight size marker (New England Biolabs, USA) were 
loaded into the wells of the gel placed in a tank of migration in which 1 L of running buffer 1X 
was added. The migration was performed at 200 V, 400 mA and 15 W per gel, until the migration 
front reached the bottom of the gel. 




Table 6 Preparation of gel electrophoresis 
Concentration buffer For 100 mL: 
- 0.5 M: Tris (Carl Roth, Germany) = 6.06 g 
- 0.4 %: SDS 20% (ITW Reagents, Spain) = 2 mL 
Adjust to pH 6.8 with HCl 
Separation buffer For 200 mL: 
- 1.5 M: Tris (Carl Roth, Germany) = 36.3 g 
- 0.4 %: SDS 20% (Carl Roth, Germany) = 4 mL 
Adjust to pH 8.8 with HCl 
Separation or running gel 10% - 1.2 mL of separation buffer 
- 1.7 mL of acrylamide 30% (Bio-Rad, USA) 
- 2.1 mL of water 
- 25 μL of APS 10% (Bio-Rad, USA) 
- 5 μL of TEMED (Bio-Rad, USA) 
Concentration or stacking gel 3.75% - 1.25 mL of concentration buffer 
- 0.5 mL of acrylamide 30% (Bio-Rad, USA) 
- 2.25 mL of water 
- 50 μL of APS 10% (Bio-Rad, USA) 
- 5 μL of TEMED (Bio-Rad, USA) 
Home-made gel (3.75-10 %) - 10 mL of running gel 10% 
- 3 mL of stacking gel 
Running buffer 10X For 1 L : 
- 30.28 g of Tris (25mM) (ICN Biomedicals, USA) 
- 144 g of glycine (0.192 M) (Merck, Germany) 
- 50 mL of SDS 20 % (ITW Reagents, Spain) 
 pH 8.7 
Loading blue 5X - 10 mL of concentration buffer 
- 10 mL of SDS 20% (ITW Reagents, Spain) 
- 5 mL of β-mercaptoethanol (Fluka Biochemika, 
Sigma-Aldrich, USA) 
- 10 mL of glycerol (Merck, Germany) 




When the electrophoresis was finished, the gel was demolded to transfer the proteins onto a PVDF 
membrane (Bio-Rad, USA). This membrane was previously hydrated in methanol 100% (VWR, 
USA) for 1 minute and then in the transfer buffer (Table 7) for at least 3 minutes. Also, both 
transfer stacks (Bio-Rad, USA) must also be immersed in transfer buffer for at least 3 minutes. 
The different elements were placed in the center of the Trans-Blot Turbo transfer cassette (Bio-
Rad, USA) in the precise order according to the protocol, from bottom to top: a transfer stack, the 
membrane, the gel and a transfer stack. The transfer was executed for 7 minutes at 2.5 A and 25 
V.  
6.5. Treatment of membranes and revelation 
After the transfer step, the membrane was incubated for 1 hour at RT with stirring with a blocking 
solution composed of diluted Odyssey blocking buffer (Li-Cor Biosciences, USA) 2x in PBS 
(Table 1) to saturate all non-specific binding sites of antibodies on the membrane. After that, the 
membrane was incubated overnight at 4 °C in the presence of the primary antibody (Table 7) 
diluted appropriately in the Li-Cor solution with Tween 20 0.1% (Merck, Germany). The next day, 
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the membrane were rinsed 3 times for 5 minutes each with PBS-Tween 20 0.1% and was then 
incubated with the secondary antibody (Table 7) coupled to a fluorochrome diluted in a Li-Cor 
solution containing 0.1% Tween for 1 hour at RT. After incubation, the membrane was washed 
again 3 times for 5 minutes each with PBS-Tween 20 0.1% and then 2 times in PBS alone. Finally, 
the membrane was dried in the dark in a hot chamber at 37 °C for one hour before being scanned 
with the Odyssey Infrared Imaging system (LI-COR Biosciences, USA). The fluorescence was 
quantified using the Odyssey V3.0 Imaging Software from the Odyssey Infrared Imager (Li-Cor 
Biosciences, USA). Relative protein expression was standardized to the abundance of tubulin. 
Table 7 Antibodies used for western blot analysis. 
Protein Primary antibody Secondary antibody 
Integrin α5 
 
Anti-integrin alpha 5  
Rabbit, 1/1 000 
(Abcam, UK) 
Alexa 488 nm 
Anti-rabbit, A-11008, 1/10 000 
(Thermo Fisher Scientific, USA) 
Integrin β3 Anti-integrin beta 3  
Mouse, 1/1 000 
(BD Biosciences, USA) 
Alexa 568 nm 
Anti-mouse, A-11004, 1/10 000 
(Thermo Fisher Scientific, USA) 




Anti-mouse, 1/10 000 
(Li-Cor Biosciences, USA) 
 
7. Scratch assay 
MDA-MB-231 cells were seeded at a density of 800 000 cells/well with RPMI-1640 medium 
(Gibco, USA) supplemented with 10% FBS (Gibco, USA) in a 35mm x 10mm polystyrene cell 
culture dish (Corning, USA) to form a confluent monolayer and incubated for approximately 
24 h at 37°C. The layer of cells was scraped to create a wound of ~1 mm width. Cellular debris 
was removed with the medium and 3 mL of fresh serum-starved medium were added, following 
by treatment with mitomycin C (Sigma-Aldrich, USA) 10 µg/mL to block the proliferation. The 
dish was placed under the Cytonote (Iprasense, France) at 37 °C to monitor the images of the 
wounds (LabCeTi). Cell migration quantification of pictures was assessed by imaging processing 
of the area that corresponds to the number of cells in the central gap. It is represented by Migration 
distance, that follows an arbitrary scale (u). The relative speed of migration was expressed in 
relative quantity after being normalized to the corresponding control.  
An additional test was carried out to assess the effect of the mitomycin on the migratory capacity. 
Variations in the protocol of the addition of mitomycin C were tested, and all of them kept the 
concentration of 10 µg/mL. First, the case is described previously, after the scratch is done, the 
debris was removed with the medium and 3 mL of fresh serum-starved medium with mitomycin 
were added. Second, mitomycin was added 3 hours before performing the scratch and removed 
from the new media. Third, mitomycin was added 3 hours before doing the scratch and kept 
within the new media. Cell migration quantification was measured as described in the previous 
paragraph.  
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8. Fibronectin-coating  
The fibronectin-coating was done with a fibronectin solution at 10 μg/mL in PBS sterile (Table 
1) from the fibronectin human plasma 1 mg/mL (Sigma-Aldrich, USA). The glass coverslips 
(Glaswarenfabrik Karl Hecht KG, Germany) in 24-well plates (Costar, USA) were coated with 
150 μL and the 35mm x 10mm polystyrene cell culture dish (Corning, USA) with 500 μL for the 
immunolabeling and the scratch assay, respectively. The solution was dried under sterile 
conditions before to seed the cells for the different experiments.  
9. LDH Assay  
Cells were seeded in 24-well plate (Costar, USA) at a density of 15 000 cells per well. 48 hours 
later, the supernatant of each well was collected in two 1.5 mL microtubes labeled as “Pellet”. 250 
μL of PBS-Triton 4% (Triton X-100 0,04 g/mL (Carl Roth, Germany) in PBS non-sterile (Table 
1) were added to the adherent cells in each well and the plates were slightly agitated at RT for 10 
minutes. The “Pellet” microtubes were centrifuged for 5 minutes at 2000 rpm at 4°C. The 
supernatant of the “Pellet” microtubes was transferred into microtubes called “Supernatant” while 
the pellets were resuspended in 250 μL of PBS-Triton 4%. The cell lysate remained in the wells. 
100 μL of each sample were placed in a 96-well plate, except for the “Lysate” samples of which 5 
μL are diluted in 95 μL of PBS-Triton 4 %. 100 μL of Cytotoxicity Detection Kit (Roche Applied 
Science, Switzerland) were added in each well and after 15 minutes of reaction, the optic density 
was read with a spectrophotometer (Bio-Rad, USA) at 490 nm and 655 nm every 15 minutes until 
at least one value reached 2. The percentage of cytotoxicity was then calculated as follows:  




10. Adhesion test 
Following the cell culture protocol (see 1.2), after cells were trypsinized and centrifuged for 5 
minutes at 1000 rpm, the supernatant was discarded, the cell pellet was resuspended and counted 
to have one million cells per each sample in 2 mL of RPMI-1640 (Gibco, USA) medium 
supplemented with10% FBS (Gibco, USA) in a 15 mL centrifuge tube (Sigma-Aldrich, USA). 
Then, 10 μL calcein-AM 1 mM (Invitrogen, USA) were added to the solution, that was incubated 
for 30 minutes at 37 °C with stirring each 5 minutes. To rinse the probe, the cell suspension was 
centrifuged at 1000 rpm for 5 minutes and the cell pellet resuspended in fresh medium, twice. After 
that, the cells were counted and seeded at 150 000 cells/well in 6-well plate (Costar, USA) in 
triplicate for labeled cells and one well for the control of non-labeled cells. After incubation for 
1.5 hours in the dark, pictures of the samples were taken with a inverted phase contrast microscope 
(Leica, Germany) before and after rise 3 times the cells with PBS (Table 1), to analyze the 
confluence related to the adhesion. Next, the cells were lysed using 200 μL/well of the diluted 
Passive Lysis Buffer 1X (Promega, USA) for 15 minutes with agitation in the dark. 80 µL/ well 
were placed in a black 96-well polypropylene plate (Thermo Fisher Scientific, USA), likewise the 
lysis buffer as a blank. The fluorescence was read by the Fluoroskan Ascent ((Thermo Fisher 
Scientific, USA) at excitation 494 nm and emission 517 nm. The percentage of adhesion was then 
calculated as follows:  
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% 𝑜𝑓 𝐴𝑑ℎ𝑒𝑠𝑖𝑜𝑛 =  
shRNA ITGA5 or ITGB3
shCtrl
 x 100 
Two alternatives of the assay were tested. At the lysis step, the procedure was done using 50 
μL/well of the diluted Passive Lysis Buffer 1X (Promega, USA) or 20 μL of lysis buffer solution 
(Table 5) for 15 minutes. After that, the quantification of proteins was achieved using Pierce 660 
nm Protein assay (Thermo Fisher Scientific, USA) (see 6.2.). 
11. PACMAN surfaces 
The surfaces and the cell migration assessment on them were performed by Sophie Ayama using 
a procedure adopted from 70. 
12. Statistical analysis 
Data from mRNA, protein, cell migration and cell size analyses are presented as mean ± SD. Two-
way ANOVA was performed followed by the post-hoc Bonferroni test (GraphPad Prism 7). A p-
































MDA-MB-231 breast cancer cells were chosen for this study. This cell line is epithelial with a 
mesenchymal-like phenotype that had already experienced the EMT, they are therefore highly 
metastatic71. Because of that, it is frequently used to study cell migration and metastasis formation. 
In order to assess and characterize the role of the ITGA5 and ITGB3 in cell migration, their 
expression was invalidated using RNA interference (siRNA) or short hairpin RNA (shRNA). 
Initially, as a confirmation of previous results, gene and protein expression of ITGA5 and ITGB3 
were assessed in samples coming from earlier studies of the PACMAN project. There were 
ITGA5-silenced or ITGB3-silenced MDA-MB-231 cells using siRNA, and ITGA5 knockdown 
cells using shRNA.  The quantification of the mRNA and the protein levels were performed by 
RT-qPCR and Western Blot analysis, respectively.  
1. Characterization of ITGA5- and ITGB3-silencing using siRNA in MDA-
MB-231 cells 
 
RNA interference was used to investigate the function of ITGA5 and ITGB3 in cell migration. 
Cells were transfected with ITGA5-targeting (siA5) or ITGB3-targeting (siB3) siRNA. 
Untransfected cells (UT) and transfected cells with siRNA RISC-Free (siRF) were used as control. 
siRF provides a reliable baseline for cellular response to lipid-RNA complexes. To evaluate the 
effectiveness of the ITG-invalidation, the mRNA relative expression was quantified by RT-qPCR 
using α-tubulin (A-TUB) as the house-keeping gene, and the protein expression was quantified by 
Western Blot analysis using A-TUB as the loading control. The values were normalized based on 
the levels obtained from UT control. The analyses were performed 72h post-transfection in four 
independent biological replicates. 
The gene expression analysis showed that the mRNA level of ITGB3 for ITGA5 knockdown cells 
rose slightly by about 27% (Figure 12A). Also, ITGA5 knockdown led to a significant decrease to 
16% (p < 0.01) in the mRNA level of the ITGA5-targeted gene (Figure 12B). On the other hand, 
the ITGB3 mRNA level decreased to 9% (p < 0.01) in ITGB3-silenced cells, without effect on the 
ITGA5 mRNA expression.  
In order to investigate whether the effect observed at the mRNA level was translated at the protein 
level, Western blotting and immunofluorescence labeling were performed at 72 h post-transfection 
(Figure 13). The results showed that protein level of ITGA5 was strongly reduced in cells 
transfected with siA5 to 7% (p < 0.001). Unexpectedly, siB3 induced a significant reduction of the 
protein ITGA5 to 58% (p < 0.01), while the mRNA level for that protein did not show a significant 
variation. We also aimed to assess the protein levels of ITGB3, but the anti-ITGB3 antibody did 
not have the expected performance and the outcomes of the Western Blot and the 



























































Figure 12. Gene expression of ITGA5 and ITGB3 in MDA-MB-231 cells. MDA-MB-231 cells were 
non-transfected (UT) or transfected using ITGA5-targeting (siA5) or ITGB3-targeting siRNA (siB3). 72 
hours post-transfection, the mRNA levels of ITGA5 (A) and ITGB3 (B) were measured by RT-qPCR 
using α-tubulin as house-keeping gene. Results are expressed in fold change after being normalized to 
the reference condition (UT), and they represent the mean of three independent replicates (n = 3). 
Statistical significance was determined by two-way ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001. 
Figure 14A confirm the effectiveness of the invalidation of ITGA5 in cells transfected with siA5. 
Immunofluorescence labeling evidenced a decrease in the labeling intensity of this protein, 
compared to UT cells, siRF or siB3-transfected cells. However, the morphology of the 
microfilaments, determined by the labeling of F-Actin, did not seem to be influenced by ITGA5 
or ITGB3 silencing. 
Additionally, the phosphorylation and localization of FAK were analyzed because of the 
importance of FAK in the formation of focal adhesion. Furthermore, FAK is involved in the 
interaction with cell-surface adhesion receptors, such as integrins. The immunofluorescence 
labeling evidenced the formation of pFAK clusters and its abundance in all focal adhesion 
complexes. However, neither pFAK abundance, nor its subcellular localization were modified in 
the invalidated cells in comparison to UT or siRF-transfected cells (Figure 15A).  
Then, MDA-MB-231 cells were characterized on 2D fibronectin-coated (FN-coated) surfaces by 
immunolabeling of ITGA5, pFAK, and F-actin (Annexe 1). This experiment was performed based 
on previous studies that highlighted the major role of ITGA5 in cells seeded onto FN-coated 
surfaces in comparison to uncoated surfaces. In these studies, ITGA5 and pFAK were observed in 


































Figure 13. Protein level of ITGA5 in MDA-MB-231 cells after control, siITGB3 or siITGA5. MDA-MDA-
MB-231 cells were non-transfected (UT) or transfected using ITGA5-targeting (siA5) or ITGB3-targeting (siB3) 
siRNA. 72 hours post-transfection, the protein level of ITGA5 was detected by Western Blotting and α-tubulin was 
used as the loading control. Results are expressed in relative quantity after being normalized to the reference 
condition (UT), and they represent the mean of independent replicates (n = 4). (A) Western blotting images. (B) 


















Figure 14.  Immunofluorescence microscopy for ITGA5 and F-Actin in MDA-MB-231 cells. MDA-MDA-
MB-231 cells were non-transfected (UT) or transfected using RISC-Free control (siRF), ITGA5-targeting (siA5) 
or ITGB3-targeting siRNA (siB3). Immunofluorescence labeling was performed at 72 h post-transfection: ITGA5 
(green), F-actin (red) and Hoechst (blue). Scale bar = 25 μm. (A) Immunofluorescence microscopic images on 
uncoated surfaces. (B) Immunofluorescence microscopic images on fibronectin-coated surfaces. 
In order to complement the characterization of ITGA5- or ITGB3-invalidated cells, ITGA5, pFAK, 
and F-actin abundance and subcellular localization were assessed by immunolabeling in cells 
cultured on fibronectin (Figure 14B and Figure 15B). In cells seeded on FN-coated surfaces, 
ITGA5 presented the cluster formation, which differed markedly from the images of cells seeded 
on uncoated-surfaces. Likewise, pFAK is grouped in clusters and present in all focal adhesion 
complexes, as was seen previously in cells seeded on uncoated surfaces. The cell morphology did 
not differ between the conditions. Furthermore, the effectiveness of the invalidation was also 
confirmed on those FN-coated surfaces since the fluorescence intensity associated to ITGA5 
labeling was strongly decreased. 
Taken together, these results indicate an effective invalidation of ITGA5 mRNA and protein in 
cells transfected with ITGA5-targeting siRNA as well as an effective invalidation of ITGB3 











Figure 15. Immunofluorescence microscopy for pFAK and F-Actin in MDA-MB-231 cells. MDA-MDA-
MB-231 cells were non-transfected (UT) or transfected using RISC-Free control (siRF), ITGA5-targeting (siA5) 
or ITGB3-targeting siRNA (siB3). Immunofluorescence labeling was performed at 72 h post-transfection: pFAK 
(green), F-actin (red) and Hoechst (blue). Scale bar = 25 μm. (A) Immunofluorescence microscopic images on 
uncoated surfaces. (B) Immunofluorescence microscopic images on fibronectin-coated surfaces. 
To characterize the role of the ITGA5 in cell migration, a wound healing assay was performed in 
cells invalidated for ITGA5 or ITGB3 using siRNA, on both uncoated and FN-coated surfaces.  
First, the relative speed of the cells to close the scratch on uncoated surfaces, compared to siRF-
transfected cells, was markedly reduced (to 38%) in cells silenced for ITGB3. Similarly, the 
relative speed of migration was diminished by ITGA5 silencing, to 57% (Figure 16B). On FN-
coated surfaces, the decrease in the migratory capacity was also observed, but to a lesser extent. 




For all the experiments, the migration of siRF-transfected cells was no different from the one of 
untransfected cells, indicating that the transfection by itself did not influence cell migration 
capacity. 
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Figure 16. Effects of ITGA5 or ITGB3 knockdown on the migratory capacity of MDA-MB-231 cells seeded 
on uncoated or FN-coated surfaces. Scratch assay was performed to assess the effects of ITGA5-silencing and 
ITGB3-silencing using siRNA on the migratory capacity of MDA-MB-231 cells seeded on uncoated surfaces (A 
and B) or on FN-coated surfaces (C and D).  Cell migration quantification of pictures was assessed by imaging 
processing and it is represented by Migration distance (u), that follows an arbitrary scale (A, C). The relative speed 




2. Characterization of ITGA5 and ITGB3 knockdown using shRNA in MDA-
MB-231 cells 
Cell transduction with a viral vector expressing shRNA allows a stable and long-term invalidation 
of the targeted gene, through its insertion in the cellular DNA. This technique has shown to be 
more powerful to study gene function than the siRNA transitory knock-down72. In the second part 
of this master thesis, MDA-MB-213 cells were thus transduced using lentiviral particles designed 
to express one shRNA. This shRNA was synthesized and cloned in the vector SHC001 (Annexe 
2). This part of the study was divided in two parts. First, in order to achieve ITGA5 knockdown, 
cells were transduced with an empty vector used as a control (shRNA Ctrl) or one of the two 
ITGA5-targeting shRNA (shRNA 126 or shRNA 124) (Annexe 2). Then, we aimed to confirm the 
characterization of ITGA5 knockdown using another ITGA5-targeting shRNA (shRNA 635). 
Secondly, we characterized ITGB3 knockdown cells using two different ITGB3-targeting shRNA 
(sh236 or sh237). shCtrl transduced cells were used as control cells. 
2.1. ITGA5 invalidation 
To assess the effectiveness of the ITGA5-invalidation using sh126 and sh124, ITGA5 expression 
has been evaluated at seven different passages post-transduction (PPT): PPT6, PPT7, PPT10, 
PPT12, PPT15, PPT18 and PPT21. The mRNA relative expression was evaluated by RT-qPCR 
using A-TUB as the house-keeping gene, and the protein expression was quantified by Western 
Blot analysis using A-TUB as the loading control.  
The results indicate that the ITGB3 mRNA levels from sh126 or sh124 knockdown cells did not 
show a significant difference (Figure 17B). Nevertheless, cells transduced with sh124 displayed 
an increased level of ITGB3 mRNA as the number of PPTs increased from PPT7 to PPT12 (Figure 
17A).   
On the other hand, cells transduced with sh126 demonstrated a decrease in the ITGA5 mRNA 
level to 28% (p < 0.001) (Figure 17D). Also, ITGA5 protein expression in the cells transduced 
with sh126 was dramatically decreased to about 20% (p < 0.001) in comparison to shCtrl (Figure 
18C). Contrarily, for the first four PPT analyzed, cells transduced with sh124 ITGA5 mRNA level 
was significantly increased by around 50% (Figure 17A), but no difference in the protein level of 
ITGA5 was observed (Figure 18B).  
Similarly, a large reduction of the abundance of ITGA5 in the sh126-transduced cells was 
evidenced by immunolabeling, but no change in the abundance of the protein was observed for 
sh124-transduced cells (Figure 19A). That assay confirms the effective invalidation of ITGA5 
using sh126 and the ineffective invalidation using sh124. For this reason, the characterization using 
sh124 was stopped at PPT12. 
In addition, the immunolabeling allowed to assess the phosphorylation of FAK and its subcellular 
localization in transduced cells and to characterize the phenotype of ITGA5-targeting sh126 and 
sh124 transduced MDA-MB-231 cells in comparison to shCtrl transduced cells. At the 
morphological level, evaluated by the labeling of the microfilaments with F-actin, no differences 




phosphorylation of FAK nor its subcellular localization was affected by ITGA5 invalidation 





































































































































Figure 17. Gene expression of ITGA5 and ITGB3 in control cells and ITGA5 knockdown MDA-MB-231 
cells.  MDA-MB-231 cells were transduced with empty vector shC001 (shCtrl) or ITGA5-targeting shRNA (sh126 
or sh124). At the passages post transduction (PPT) 6, 7, 10, 15, 18, and 21. The mRNA levels of ITGB3 (A and B) 
and ITGA5 (C and D) were measured by RT-qPCR using α-tubulin mRNA as house-keeping gene. Results are 
expressed in fold change after being normalized to the reference condition (shCtrl). For (B and D), results are the 
mean ± SD (standard deviation) of the passages (n = 6). Statistical significance was determined by two-way 


















































































Figure 18. Protein level of ITGA5 in control cells and ITGA5 knockdown MDA-MB-231 cells. MDA-MB-
231 cells were transduced with empty vector shC001 (shCtrl), ITGA5-targeting shRNA (sh126 or sh124) at the 
passages post transduction (PPT) 6, 7, 10, 15, 18, and 21. Protein levels of ITGA5 (A and B) were detected by 
Western Blotting (C) and α-tubulin was used as loading control. Results are expressed in relative quantity after 
being normalized to the reference condition (shCtrl). For (B), results are the mean ± SD (standard deviation) of the 

























Figure 19. Immunofluorescence microscopy for ITGA5, pFAK and F-Actin in MDA-MB-231 cells. MDA-
MB-231 cells were transduced with empty vector shC001 (shCtrl) or ITGA5-targeting shRNA (sh126 or sh124). 
Immunofluorescence labeling was performed at PPT12 post-transduction: F-actin (red) and Hoechst (blue). Scale 
bars: 25 μm. (A) Immunofluorescence microscopic images for ITGA5 (green). (B) Immunofluorescence 
microscopic images for pFAK (green). 
Nevertheless, a difference in the confluence of the cells transduced with sh126 was observed. To 
evaluate if it can be explained by a cytotoxicity due to the transduction with ITGA5-targeting 
shRNA, at the PPT7, PPT10, PPT12, PPT15 and PPT18, the cells in 24-well plate were incubated 
for 48 hours in normal medium, and then, a LDH assay was performed. (Figure 20) shows that 
there was no considerable level of cytotoxicity, based on the threshold of 20%, neither in control 








































Figure 20.  Lactate dehydrogenase cytotoxicity assay in control cells and ITGA5 knockdown MDA-MB-231 
cells. MDA-MB-231 cells were transduced with empty vector shC001 (shCtrl) or ITGA5-targeting shRNA (sh126 
or sh124). At the passages post transduction (PPT) 7, 10, 12, 15 and 18; cells were seeded in in 24-well plate and 
incubated for 48 hours with the RPMI-1640 medium supplemented with 10% fetal bovine serum, and then the 
assay was performed. The results are presented as the percent cytotoxicity of the maximum LDH release control 
according to the manufacturer's instructions, where values of 100% indicate total cellular toxicity and the non-
cytotoxicity threshold is under 20%. The assay was done on five biological independent replicates (n = 5), each 
one with three technical replicates (n = 3).  
The characterization was stopped at PPT21, because the cells transduced using sh126 diverged 
(Annexe 3). However, the quantification of the mRNA and protein level of ITGA5 at PPT21 
confirm the continuous invalidation up to this last passage. 
For all the experiments, shCtrl-transduced cells were no different from the one of untransfected 
cells. Additionally, the specific shCtrl control had the advantage to ensure that the effects observed 
after the transduction are the result of gene silencing and not merely the result of the introduction 
of the shRNA, like toxicity or gene expression changes due to activation of different pathways. 
Because of that, the use of untransfected cells was stopped at PPT8 and shCtrl was used as the 
only control. 
Additionally, cells were transduced with sh635, another ITGA5-targeting shRNA, to confirm the 
results obtained using sh126. This shRNA was already validated in the cell line MCH58 with a 
mean knockdown level of 80% (Sigma information). Nevertheless, the phenotype obtained after 
the invalidation was very strong with a total loss of cell adhesion to the culture flasks. Cells were 
presenting low confluence that did not allow to achieve enough number of cells in usual cell culture 
conditions to characterize them (Annexe 4). 
Finally, the role of ITGA5 in the migratory capacity of the shRNA ITGA5 knockdown cells was 
evaluated. Due to the ineffective invalidation of ITGA5 in cells trtansduced with sh124, the scratch 
assay was performed to compare sh126 to shCtrl. The cells with the invalidation of ITGA5 did not 
present a significant difference in the relative speed of migration compared to shCtrl. This 





2.2. ITGB3 invalidation 
During the second part, cells were invalidated for ITGB3 using two different ITGB3-targeting 
shRNA (sh236 or sh237). The test of sh236 had to be stopped at PPT7 because of contamination. 
First, to estimate the effectiveness of the invalidation, ITGA5 and ITGB3 expression was evaluated 
at three different passages post-transduction (PPT): PPT7, PPT10, and PPT12.  
The results indicate that for ITGB3-invalidated cells using sh237, the level of ITGB3 strongly 
diminished, to 19% (p < 0.05) (Figure 21B). However, for these ITGB3-invalidated cells, we 
observed that the level of ITGA5 rose substantially, by around 56% (p < 0.05) (Figure 21D). In 
parallel, we observed a significant increase in ITGA5 protein level, which was two-fold higher 
than the control value, up to about 210% (p < 0.05) (Figure 22C). The overexpression of the protein 
ITGA5 in sh237-transduced cells was also detected in the immunofluorescence labeling of cells 
seeded on uncoated surfaces, as well as on FN-coated surfaces, in which it was observed in clusters 
(Figure 23). 
In second place, the phosphorylation of FAK and its subcellular localization in transduced cells 
were evaluated using immunolabeling. Also, the phenotype of the sample cells was characterized 
in comparison to shCtrl transduced cells. At the morphological level, analyzing the microfilaments 
by the labeling of F-actin, no difference was observed in ITGB3-knockdown cells. Furthermore, 
neither the phosphorylation of FAK, nor its subcellular localization was changed in comparison to 
control cells seeded on uncoated or FN-coated surfaces (Figure 24).  However, cells seeded on 
uncoated surfaces seemed to be smaller than on FN- coated surfaces, for each sample. To confirm 
the observation, cell sizes were measured by confocal microscopy (Annexe 6) and for all the 
conditions, cell sizes were lower for cells seeded on uncoated surfaces than for cells seeded on 
FN-coated surfaces. 
Through the PPTs, difference of confluence between the control cells and the invalidated cells, for 
both ITGA5 and ITGB3 silencing, was observed (Annexe 7). Since cytotoxicity did not explain 
the lower confluence of sh126-transduced cells, a pilot test to evaluate the detachment of the cells 
was performed. The results obtained by the different methods did not allow to conclude that the 






















































































Figure 21. Gene expression of ITGA5 and ITGB3 in control cells, ITGA5 or ITGB3 knockdown MDA-MB-
231 cells.  MDA-MB-231 cells were transduced with empty vector shC001 (shCtrl) or ITGB3-targeting shRNA 
(sh237). At the passages post transduction (PPT) 7, 10 and 12, the mRNA levels of ITGB3 (A and B) and ITGA5 
(C and D) were measured by RT-qPCR using α-tubulin mRNA as house-keeping gene. Results are expressed in 
fold change after being normalized to the reference condition (shCtrl). For (B and D), results are the mean ± SD 
(standard deviation) of the three passages (n = 3). Statistical significance was determined by two-way ANOVA; 



























































Figure 22. Protein level of ITGA5 in control cells, ITGA5 or ITGB3 knockdown MDA-MB-231 cells. MDA-
MB-231 cells were transduced with empty vector shC001 (shCtrl) or ITGB3-targeting shRNA (sh237) at the 
passages post transduction (PPT) 6, 7 and 10. Protein levels of ITGA5 (A and B) were detected by Western Blotting 
(C) and α-tubulin was used as loading control. Results are expressed in relative quantity after being normalized to 
the reference condition (shCtrl). For (B), results are the mean ± SD (standard deviation) of the three passages (n = 









Figure 23.  Immunofluorescence microscopy for ITGA5 and F-Actin in MDA-MB-231 cells. MDA-MB-231 
cells were transduced with empty vector shC001 (shCtrl) or ITGB3-targeting shRNA (sh237). 
Immunofluorescence labeling was performed at passage post-transduction (PPT) 13: ITGA5 (green), F-actin (red) 
and Hoechst (blue). Scale bars: 25 μm. (A) Immunofluorescence microscopic images on uncoated surfaces. (B) 









Figure 24.  Immunofluorescence microscopy for pFAK and F-Actin in MDA-MB-231 cells. MDA-MB-231 
cells were transduced with empty vector shC001 (shCtrl) or ITGB3-targeting shRNA (sh237). 
Immunofluorescence labeling was performed at passage post-transduction (PPT) 13: pFAK (green), F-actin (red) 
and Hoechst (blue). Scale bars: 25 μm. (A) Immunofluorescence microscopic images on uncoated surfaces. (B) 






3. Characterization of ITGA5 and ITGB3 co-invalidated MDA-MB-231 cells 
Based on the current knowledge of the interaction and regulation between these two integrins, 
ITGA5 and ITGB3 and since we observed an influence of ITGB3 invalidation on ITGA5 
expression, we though that co-invalidation of both integrins would be interesting.  
First, to evaluate the effectiveness of the co-invalidation, ITGB3-invalidated cells using sh237 
were invalidated for ITGA5 using siRNA (ITGB3 KO-siA5), ITGA5 and ITGB3 expression were 
assessed at 72 h post-transfection.  ITGB3-invalidated cells using sh237 (ITGB3 KO) were used 
as a control, as well as transfected cells with siRNA RISC-Free (ITGB3 KO-siRF) that were used 
as the transfection control. The mRNA relative expression was evaluated by RT-qPCR using A-
TUB as the house-keeping gene, and the protein expression was quantified by Western Blot 
analysis using A-TUB as the loading control.  
The results indicate that the co-invalidation was effective because ITGB3 KO-siA5 cells displayed 
a substantially decrease in the ITGA5 mRNA level, to 15% and a reduced level of the ITGA5 
protein level (to 1%) compared to ITGB3 KO-siRF control cells.  For ITGB3 mRNA level, ITGB3 
KO-siA5 cells did not show a significant difference from the ITGB3 KO-siRF control cells 
(Annexe 9). Similarly, a large reduction of the abundance of ITGA5 in co-invalidated cells was 
evidenced by immunolabeling in cells seeded on both uncoated and FN-coated surfaces compared 
to ITGB3 KO control cells (Figure 25). 
Additionally, the transfection seemed to have an effect by itself because ITGB3 KO control cells 
displayed a decrease in the ITGA5 mRNA level (to 60%) in comparison to ITGB3 KO-siRF cells. 
That effect was also seen at protein level, since ITGB3 KO cells had a lower protein level of 
ITGA5 by around 20% compared to ITGB3 KO-siRF control cells (Annexe 10). The 
overexpression of ITGA5 protein in ITGB3 KO-siRF control cells was also observed by 
immunofluorescence labeling.  
On the other hand, the phosphorylation of FAK and its subcellular localization did not differ in co-
invalidated cells compared to the corresponding control cells when seeded on uncoated or FN-
coated surfaces (Figure 26). Nevertheless, the cell phenotype on FN-coated surfaces differ from 
the one of cells seeded on uncoated-surfaces because they had a significant smaller size, as was 
seen in the second part of the shRNA characterization (Annexe 11).  
In addition, cell migratory capacity was evaluated in the cells co-invalidated for the two integrins 
of interest. In this case, the ITGB3 KO-siRF control cells or ITGB3 KO-siA5 co-invalidated cells 
had a decrease in the relative speed in comparison to ITGB3 KO control. Nevertheless, the 
migratory relative speed of ITGB3 KO-siA5 cells did not have a significant reduction compared 
with the transfection control ITGB3 KO-siRF (Annexe 12). 
Finally, the migratory capacity of MDA-MB-231 cells was assessed under three different protocols 
of exposition to the mitomycin (See Material and Methods). The results did not evidence any 

























Figure 25.  Immunofluorescence microscopy for ITGA5 and F-Actin in MDA-MB-231 cells upon co-
invalidation. ITGB3-invalidated MDA-MB-231 cells transduced with ITGB3-targeting shRNA (sh237) were non-
transfected (UT) or transfected using RISC-Free control (siRF) or ITGA5-targeting (siA5). Immunofluorescence 
labeling was performed at 72 h post-transfection: ITGA5 (green), F-actin (red) and Hoechst (blue). Scale bar = 25 
μm. (A) Immunofluorescence microscopic images on uncoated surfaces. (B) Immunofluorescence microscopic 




























Figure 26.  Immunofluorescence microscopy for p-FAK and F-Actin in MDA-MB-231 cells upon co-
invalidation. ITGB3-invalidated MDA-MB-231 cells transduced with ITGB3-targeting shRNA (sh237) were non-
transfected (UT) or transfected using RISC-Free control (siRF) or ITGA5-targeting (siA5). Immunofluorescence 
labeling was performed at 72 h post-transfection: p-FAK (green), F-actin (red) and Hoechst (blue). Scale bar = 25 
μm. (A) Immunofluorescence microscopic images on uncoated surfaces. (B) Immunofluorescence microscopic 






















V. DISCUSSION, PERSPECTIVES 
AND CONCLUSION  
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1. Discussion and perspectives 
Metastasis is the leading cause of breast cancer mortality5. Indeed, the elucidation of the 
mechanism related to this process is a primordial objective to develop better diagnostic tools and 
treatments. Previous studies showed that the expression level of ITGA5 may modulate cell 
proliferation and that high levels of ITGA5 expression are required for metastasis to lymph nodes 
and lungs in breast cancer models73. Also, its expression in clinical biopsies is associated with an 
increased risk of mortality and was determined as an unfavorable prognosis factor74.  
MDA-MB-231 metastatic breast cancer cell line was the model chosen to characterize the role of 
ITGA5 in cell migration in vitro. To achieve this main objective, the expression of ITGA5 and 
ITGB3 was invalidated. Firstly, the invalidation was done using siRNA, and secondly, using 
shRNAs stably expressed in lentiviral-transduced cells.   
The first objective of the study was to assess the efficiency of integrin invalidation. Therefore, the 
levels of mRNA and protein were evaluated by RT-qPCR and Western Blot analysis respectively. 
Also, the abundance of ITGA5 protein and its subcellular localization were evaluated using 
immunofluorescence labeling. Likewise, pFAK and F-actin proteins were studied by 
immunolabeling, in order to observe whether ITGA5 or ITGB3 invalidation would alter the 
formation of focal adhesions or the cell morphology.  
1.1. Effective ITG-invalidation using siRNA and shRNA 
In the first part, ITGA5- and ITGB3-silencing using siRNA was efficient. ITGA5 knockdown cells 
showed a diminution in the mRNA and in the protein levels of ITGA5. Similarly, ITGB3 
knockdown cells had a lower ITGB3 mRNA level, whereas the ITGA5 mRNA level did not 
change. Despite this, ITGB3 knockdown cells had a significant decrease in ITGA5 protein level, 
that can be explained by variation in the transcription, mRNA decay, translation or protein 
degradation, that all together determine the protein abundance. Nevertheless, ITGA5 knockdown 
cells showed a slight increase in ITGB3 mRNA level, that could suggest an interconnexion 
between both integrins.  
To proceed with a further characterization, the cells were invalidation in the long term. After 
performing the invalidation using shRNA and in accordance with the immunolabeling, mRNA and 
protein levels of ITGA5, the results demonstrated that the invalidation using sh126 was effective, 
but it was not using sh124. In the last case, literature was not found reporting the use of this 
sequence to perform the ITGA5 invalidation or its lack of effectiveness. Given that, it is suggested 
that could be for two reasons: first, an inefficient transduction process, or second, an off-target 
activity. Analyzing the first option, the transduction followed the same protocol as was done for 
shCtrl and sh126; therefore, it did not seem to be the cause of the infective knockdown of ITGA5. 
Consequently, it is more probable that it is caused as a consequence of an off-target effect.  
In turn, ITGB3 was also efficiently invalidated using sh237, regarding to the results that showed a 
diminution in mRNA and protein levels of ITGB3.  
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1.2. Phenotypic variations induced by ITG-invalidation 
During the second part, to validate the results obtained from the cells invalidated using sh126, 
another ITGA5-targeting shRNA (sh635) was tested. The strongest phenotype was observed from 
the invalidated cells compared to shCtrl. The cells were not able to proliferate enough to proceed 
for their characterization. This strong phenotype allows to hypothesize that the absence of ITGA5 
could affect other important cellular processes where the integrin is involved. For example, a 
hypothesis in this case is that the lack of proliferation can be due to a loss of cell-surface adhesion. 
This idea will be developed later in the discussion. Additionally, in order to study the roles and 
interaction of the integrins of interest, ITGB3-invalidated cells using two different shRNA (sh236 
and sh237) were also characterized. 
During the study, the phenotype of ITGA5- and ITGB3-invalidated cells and the control cells did 
not show difference between them at a morphological level or in the formation of focal adhesion, 
both characteristics assessed by immunofluorescence labeling of polymerized actin (F-actin) and 
phosphorylation of FAK. 
Nevertheless, a preceding study found a significant decrease in the focal adhesion area in the 
ITGA5-invalidated cells, showing a close relationship between the integrin and the formation of 
focal adhesion73. The evaluation of the formation of the focal adhesion complex could be done 
through the analysis of another protein downstream in the cascade. Proteins such as vinculin or 
paxillin could help to elucidate the relation between ITGA5 and the maturation of the complete 
formation of focal adhesion and later its role in the signalization that depends on that process. 
1.3. Effect of ITG invalidation and FN-coating on cell phenotype 
Although there were not morphologic variations, differences in cell confluence were observed in 
cells transduced with sh126 or sh237 compared to the control cells. After the evaluation of the 
cytotoxicity by LDH assay in cells transduced with ITGA5-targeting shRNA, it was concluded 
that was no considerable level of cytotoxicity neither in shCtrl cells nor in the invalidated cells, 
based on the threshold of 20%. Since cytotoxicity did not explain the lower confluence of sh126-
transduced cells and knowing that integrins play a crucial role in ECM-cell and cell-cell 
adhesion47, a pilot test to evaluate the cell detachment was carried out. The test was adjusted to 
achieve a trustable analysis of cell adhesion in MDA-MB-231 cell, but the results obtained were 
not conclusive. A hypothesis based on the data suggests that the difference in cell confluence could 
be related to not just a diminution in cell adhesion at the first moment of cell-surface interaction, 
but to effects in cell adhesion during cell division. In order to determine the cause of the confluence 
difference, this observation will be investigated further in the following part of the PACMAN 
project. Other adhesion assays can be used at different timings to elucidate the main cause. If the 
effect is due to cell-surface adhesion inhibition, it will be seen in a short time and before cell 
proliferation. Additionally, to confirm that the confluence difference is not because of alterations 
in cell proliferation itself, it is possible to do a BrdU flow cytometry, that will indicate cells that 
are actively replicating their DNA during the assay.  
Cell adhesion also seemed to be involved in the variation or compensatory effect between the 
integrins. It is reflected in the difference in the mRNA level of the integrin that was not invalidated 
that changed along with the PPTs. The decrease in the mRNA level can be due to the fact that the 
cells with the strongest phenotype have less cell adhesion capacity and those cells were discarded 
during the process of the cell culture. Therefore, cells analyzed in the later PPTs could have been 
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selected and hence, displayed a less strong phenotype. Another hypothesis can be because cells 
adapted to the new conditions and the expression of one integrin could increase to compensate the 
absence of the other integrin.  
Additionally, an effect of FN-coating in cell adhesion was detected through the cell size observed 
by Z-series. The bigger cell size observed for cells seeded on FN-coating throughout the whole 
work may correspond to the enhancement of cell adhesion because of the integrins activation 
(Annexe 144).  Also, cell migration on FN-coated surfaces displayed a higher speed than in 
uncoated surfaces for both, control and ITG-invalidated cells. It is probably due to the increase in 
the cell-surface interactions. 
1.4. Effects of ITG invalidation on cell migratory capacity 
Since the main objective of this master thesis is to study the role of ITGA5 in cell migration in a 
model of metastatic breast cancer, scratch assays were performed to assess the migratory capacity 
of the cells using invalidated using siRNA or shRNA. First, the ITGB3 invalidation using siRNA 
had a marked effect reducing the relative speed of the cells to close the scratch, as was expected 
according to previous results obtained in the PACMAN project. Similarly, other studies showed 
impairment in the migratory and invasive potential of cancer cells by ITGB3 knockdown75.  
The effect of ITGA5 on cell migration has been previsouly studied, showing that ITGA5 
expression promotes ITGA5-mediated cell adhesion and migration supporting 
breast cancer metastasis75. However, in this master thesis, the migration was only slightly 
diminished by ITGA5 silencing using siRNA. It could be assumed that the effect could not be seen 
because of the cells did not have enough time to adjust to the ITGA5 invalidation. Hence, with the 
objective to assess the effect of this integrin on this process, lentiviral vectors were used to 
transduce the cells with ITGA5-targeting shRNA, achieving a constitutive knockdown.  
The results showed that the migratory capacity of ITGA5 knockdown cells did not differ in 
comparison to the control cells. This observation was performed for cells seeded on uncoated 
surfaces and on FN-coated surfaces. Given the microenvironment where the scratch assay was 
performed, a 2D model with low-FN, the results can be explained based on previous studies that 
reported the role of ITGA5 under similar conditions. For example, ITGA5 modulated single cell 
migration within a complex multicellular spheroid as well as single cell migration within 3D 
collagen-fibronectin gels but did not alter cell migration in 2D73. Also, it has been previously 
reported that ITGA5 can promote invasive migration and cell dispersion in FN-rich 
microenvironment76, while, ITGB3 promotes migration in low-FN ECM77. Even if the experiment 
on FN-coated surfaces tried to approach to those conditions and the activation ITGA5 was 
observed, when the scratch is done, the FN layer is removed, preventing the possibility to evaluate 
the migration on FN-rich microenvironment. So, ITGA5 could not express its migratory properties 
under the conditions used here.  
To continue with the characterization of ITGA5 and ITGB3 in cell migration, a migration test was 
done upon co-invalidation. The migratory capacity of the co-invalidated cells did not differ from 
the ITGB3 KO-siRF control. The difference in cell migration of co-invalidated and ITGB3 KO-
siRF cells compared to ITGB3 KO control seems to be related to the transfection process and not 
to the absence of ITGA5. 
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Finally, results from the cell migration assay suggested that ITGA5 did not play the main role in 
distal cell migration in the model and conditions tested here. First, based on the analysis and results 
from previous researches, arise the alternative to test our cell model on FN-coated 3D models, 
where ITGA5 seems to have a determinant role in the migration and invasion. Our results showed 
that ITGA5 is not activated on uncoated surfaces, contrary as it was observed with its clusterization 
on FN-coated surfaces, that confirms its activation. Therefore, the ITGA5 invalidation could not 
have a big relevance under the conditions analyzed because when the integrin is inactive, it does 
not have a main role in the adhesion or migration. At the same time, for the migration assay are 
required more replicates and standardized method of testing and analyzing. Other assays in 2D or 
3D could be used to validate the results (Annexe 15); for example, Boyden chamber or spheroid 
migration assay.  
Second, the phosphorylation of FAK was observed in all the cases studied, even in the co-
invalidated cells. The confirmation of the formation of focal adhesion supports the slight or 
insignificant difference of the cell migratory capacity given that focal adhesion formation has been 
demonstrating to correlate with 2D cancer cell motility78. It means that other compounds, more 
than FN, enhanced cell-surface interactions, activating the formation of focal adhesion and 
inducing cell migration, no matter the lack of ITGA5 or ITGB3. For example, it should be taken 
into account that the medium used in cell culture was supplemented with growth factors, that 
activated the epithelial growth factor receptor (EGFR). EGFR signaling can modulate adhesion by 
the redistribution of ITGA5 and ITGB3 and via an increase in the phosphorylation of FAK79. 
Additionally, another interesting point of future research could be to test if the MDA-MB-231 cells 
could produce FN by themselves and, hence, autoactivate their migration.  
Based on these findings, it is possible to conclude that the migration function of ITGA5 is closely 
associated with the microenvironment the cells resided in and these cells can adopt a mode of 
migration that fits the local conditions, applying the regulation of those integrins, in this case: 
ITGA5 and ITGB3. That result implies that cell migration is a complex process where many actors 
are involved and can compensate the absence of some proteins. ITGA5 and ITGB3 are not 
indispensable for the formation of focal adhesion neither for the migratory cell in the model studied 
here. A deeper study should be carried that can establish the relation between the different actors. 
1.5. Interaction and regulation between ITGA5 and ITGB3 
ITGA5 knockdown cells at early PPTs showed a higher ITGB3 mRNA level than shCtrl-
transduced cells, but a later diminution of that level at the increased of the PPTs. These events 
were also observed during the first part of the project. Likewise, the early increase in ITGB3 
mRNA expression supportS the findings observed during the ITGA5 invalidation using siRNA. 
However, because of the duration of the experiment, the later reduction of the non-invalidated ITG 
mRNA level could not be seen.  In addition to that, ITGB3 knockdown cells showed the same 
behavior for the ITGA5 mRNA levels, an overexpression at early PPTs and a continuous decreasE 
of that level at later PPTs.   
The interactions between ITGA5 and ITGB3 that influence their gene and protein expression, have 
been previously described in the literature, suggesting that ITGA5 regulates the function of ITGB3 
and vice versa, during some processes like migration in vitro or angiogenesis in vivo80. 
Furthermore, those interactions can vary based on the type of model studied. For example, they 
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are different depending on the type of cancer and the state of it. In fact, this variability increases 
the complexity of the study. 
ITGA5 and ITGB3 bind to similar ligands but can act differently. While both promote migration, 
they elicit different signaling responses and cell motility outcomes. Indeed, they mutually could 
suppress or regulate each other in different ways81. To illustrate, ITGB3 and its recycling impair 
ITGA5 recycling and its pro-invasive activity77. ITGB3-recycling is promoted in the absence of 
FN and it stimulates directionally persistent lamellipodial migration in 2D and invasion into 3D 
ECM, but ITGB3-recycling pathway suppresses invasive migration in the presence of FN. 
Consequently, when ITGB3 or its recycling is inhibited, ITGA5 recycling drives random cell 
motility in 2D and promotes 3D invasion into FN-rich ECM37. Therefore, it is important to 
understand the interrelationship between these two integrins and the reciprocal influence on their 
gene and protein expression, specifically their role in motility of cancer cells. Given that the 
complex underlying mechanism of ITGA5 and ITGB3 regulation remains undetermined, one 
method to evaluate the effect of ITGB3 on ITGA5 could be done exposing ITGB3-invalidated 
cells to variation in the microenvironment conditions, such as quantity of FN or presence of other 
adhesion molecules, then to measure the gene and protein expression of ITGA5. In this way, 
determining under which specific conditions ITGB3 regulates ITGA5 could be achieved.  
1.6. Perspectives  
The complexity of cell migration leads to think that other integrin candidates involved in the 
process can be studied. In particular, integrin αvβ6 (ITGB6) has been found upregulated in many 
breast cancer samples and associated with poor prognosis46. This upregulation is caused by the 
abnormal high expression of MMP-9. Previous studies showed that FN can be degraded into 
fragments by MMP-9 in vitro, exposing different motifs of FN like RGD for proliferation in FNIII 
or IGD for migration in FNI46. The degradation of the ECM is a common characteristic in cancers. 
Similarly, it should be taken in count that the crosstalk in processes like EMT, between different 
signal pathways and molecules, is crucial. To illustrate, integrins have been implicated in the 
communication with cadherins during cancer invasion and metastasis82. To elucidate that 
relationship between those adhesion molecules, it could be convenient to analyze epithelial and 
mesenchymal markers, such as E-cadherin and N-cadherin, respectively. 
A study that supports the role of ITGA5 in cell migration in 3D models, found that the increased 
ITGA5 recycling is linked to the invasion in a FN-rich 3D microenvironment through the 
generation of Rho-driven invasive cellular protrusions, unique to cells in 3D to promote 
migration83. And based on the studies that exposed the difference between 2D and 3D motility in 
multiple contexts, further in the PACMAN project it could be interesting to characterize the role 
of ITGA5 related to the Rho signaling pathway in a complex 3D environment. For example, 
migrating cells of breast, pancreatic, and prostate cancers did not display lamellipodial structures 
in 3D, like spheroids, but they have unique dendritic protrusions73.  
One issue to elucidate the role of those integrins is due to the multiple functions that they have into 
the cell. Depending on many variables, those integrins can have a supportive or suppressive role 
in the cell migration regarding the literature. One possibility that should solve that problem is the 
use of machine learning to assess the role and the relevance that these proteins have on each state. 
Machine learning is a computational science that provides computers with the ability to create 
algorithms that can learn from and make predictions about data84. 
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In the PACMAN projects, after the separation of the cell according to its migratory phenotype, 
and perform the single-cell RNA sequencing, that its already ongoing, machine learning could be 
applied in order to show the different interactions and how they differ depending on the migratory 
state. Also, the analysis will be specific for our breast cancer model and could bring possible 
therapeutic and diagnosis targets. Moreover, these targets can be specific for each phenotype. The 
information given by this application can be posteriorly validated by analyzing samples from the 
cancer biobanks. Currently, some studies already had used artificial intelligence to study breast 
cancer, but especially to assess the risk factors or just based on the genetic signature85. The 
application to study cell migration is just starting, like in the University of Glasgow, that has new 
research project that focus on using machine learning to understand the drivers of cancer spread 
and cell migration. An interdisciplinary collaboration could help also to understand this complex 
process in cancer models. 
 
2. Conclusion 
The roles of integrins in cancer have demonstrated a complex molecular mechanism involved in 
their biological function in different steps of cancer progression and metastasis. Integrin function 
and expression determine cancer cell behavior and characteristics. Integrins play a main role in 
metastasis because of their diverse roles in cell survival, motility, adhesion, and migration. 
Even if ITGA5 and ITGB3 have been associated with cancer progression and metastasis in various 
types of cancer, their role has not been completely elucidated. Both integrins are involved in breast 
cancer metastasis, but they can act in different ways regarding the state of the disease. In MDA-
MB-231 cell line, a model of metastatic breast cancer, ITGA5 did not show a significant 
correlation with cell migratory capacity, under the tested conditions. 
Finally, the results will be validated using PACMAN surfaces (IGDQ-exposing surfaces-gradient-
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Annexe 1. Immunofluorescence microscopy for ITGA5, pFAK and F-Actin in MDA-MB-231 cells seeded 
on uncoated or fibronectin-coated surfaces. MDA-MB-231 cells were seeded on uncoated surfaces (Ctrl) or 
fibronectin-coated surfaces (FN): F-actin (red) and Hoechst (blue). Scale bars: 25 μm. (A) Immunofluorescence 














B shRNA 126 
CCGGAGGCAGATCCAGGACTATATTCTCGAGAATATAGTCCTGGATCTGCCTTTTTTG 




Target: CDC region 
 
D shRNA 653 
CCGGCTCCTATATGTGACCAGAGTTCTCGAGAACTCTGGTCACATATAGGAGTTTTT 
Target: CDC region 
 
E shRNA 236 
CCGGCCTTAGCCTTTGTCCCAGAATCTCGAGATTCTGGGACAAAGGCTAAGGTTTTT 
Target: 3’UTR region 
 
F shRNA 237 
CCGGGATGCAGTGAATTGTACCTATCTCGAGATAGGTACAATTCACTGCATCTTTTT 
Target: CDC region 
 
Annexe 2. SHC001 vector and short hairpin RNA sequences for ITGA5 or ITGB3 knockdown. Cells were 
transduced with lentiviral particles containing the SHC001 vector (A). Lentiviral construct integrates into the host 
genome and provides stable expression of the short hairpin RNA that target ITGA5 mRNA (shRNA 126, shRNA 
124 or shRNA653) or ITGB3 mRNA (shRNA 236 or shRNA 237). Sequences shRNA 126 (B), shRNA124 (C), 



















Annexe 3.  MDA-MB-231 cell transduced using sh126. Cell morphology of cells transduced with sh126 (A). at 




Annexe 4. MDA-MB-231 cell transduced using sh635. Strong cell phenotype at PPT2 after the invalidation of 
ITGA5 using sh635, that did not allow to achieve the confluence required to perform the characterization of the 





















































































































Annexe 5. Effects of ITGA5 knockdown on the migratory capacity of MDA-MB-231 cells seeded on uncoated 
or FN-coated surfaces. Scratch assay was performed to assess the effects of  ITGA5 knockdown using shRNA on 
the migratory capacity of MDA-MB-231 cells seeded on uncoated surfaces (A and B) or on FN-coated surfaces (C 
and D). Cell migration quantification of pictures was assessed by imaging processing and it is represented by 
Migration distance (u), that follows an arbitrary scale (A, C). The relative speed of migration is expressed after 















































Annexe 6. Cell sizes measured by confocal microscopy of MDA-MB-231 cells. MDA-MB-231 cells were 
transduced with empty vector shC001 (shCtrl), ITGA5-targeting shRNA (sh126) or ITGB3-targeting shRNA 
(sh237). Cell sizes were measured by z-series stacking at the passages post transduction (PPT) 13 on uncoated and 
FN-coated surfaces. Results represent the mean of independent replicates (n = 30). Statistical significance was 








Annexe 7. Difference in confluence between the samples of MDA-MB-231 cells. MDA-MB-231 cells were 
transduced with empty vector shC001 (shCtrl), ITGA5-targeting shRNA (sh126) or ITGB3-targeting shRNA 














































































Annexe 8.  Adhesion assay for MDA-MB-231 cells. MDA-MB-231 cells were transduced with empty vector 
shC001 (shCtrl), ITGA5-targeting shRNA (sh126) or ITGB3-targeting shRNA (sh237 or sh236). Adhesion 

















































Annexe 9. Gene expression of ITGA5 and ITGB3 in MDA-MB-231 cells upon co-invalidation. ITGB3-
invalidated MDA-MB-231 cells transduced with ITGB3-targeting shRNA (sh237) were non-transfected (ITGB3 
KO-Ctrl) or transfected using RISC-Free control (ITGB3 KO-siRF) or ITGA5-targeting (ITGB3 KO-siA5). 72 
hours post-transfection, the mRNA levels of ITGA5 and ITGB3 were measured by RT-qPCR using α-tubulin as 
house-keeping gene. Results are expressed in fold change after being normalized to the reference condition (UT) 























































Annexe 10. Protein level of ITGA5 in control cells, in MDA-MB-231 cells upon co-invalidation. ITGB3-
invalidated MDA-MB-231 cells transduced with ITGB3-targeting shRNA (sh237) were non-transfected (ITGB3 
KO-Ctrl) or transfected using RISC-Free control (ITGB3 KO-siRF) or ITGA5-targeting (ITGB3 KO-siA5). 72 
hours post-transfection, the protein level of ITGA5 was assessed by Western Blot analysis and α-tubulin was used 
as the loading control. Results are expressed in relative quantity after being normalized to the reference condition 








































































Annexe 11. Cell sizes measured by confocal microscopy of MDA-MB-231 cells upon co-invalidation. ITGB3-
invalidated MDA-MB-231 cells transduced with ITGB3-targeting shRNA (sh237) were non-transfected (ITGB3 
KO-Ctrl) or transfected using RISC-Free control (ITGB3 KO-siRF) or ITGA5-targeting (ITGB3 KO-siA5). Cell 
sizes were measured by z-series stacking at 72 hours post-transfection on uncoated and FN-coated surfaces. Results 
represent the mean of independent replicates (n = 30). Statistical significance was determined by two-way 



































































































Annexe 12. Effects of ITGA5 knockdown on the migratory capacity of MDA-MB-231 cells after co-
invalidation test. ITGB3-invalidated MDA-MB-231 cells transduced with ITGB3-targeting shRNA (sh237) were 
non-transfected (ITGB3 KO-Ctrl) or transfected using RISC-Free control (ITGB3 KO-siRF) or ITGA5-targeting 
(ITGB3 KO-siA5). 72 hours post-transfection, scratch assay was performed to assess the effects of ITGA5-
silencing and ITGB3-silencing on the migratory capacity of MDA-MB-231 cells. Cell migration quantification of 
pictures was assessed by imaging processing and it is represented by Closed area (Scratch), that follows an arbitrary 
scale. The relative speed of migration is expressed after being normalized to the corresponding control. 
A 













































Annexe 13. Effects of mitomycin treatment on the migratory capacity of MDA-MB-231 cells. Scratch assay 
was performed to assess the effects of mitomycin treatment (see Material and Methods) on the migratory capacity 
of MDA-MB-231 cells. Test 1: after the scratch is done, the debris was removed with the medium and 3 mL of 
fresh serum-starved medium with mitomycin were added. Test 2: mitomycin was added 3 hours before 
performing the scratch and removed from the new media. Test 3: mitomycin was added 3 hours before doing 
the scratch and kept within the new media. Cell migration quantification of pictures was assessed by imaging 
processing and it is represented by Closed area (Scratch), that follows an arbitrary scale. The relative speed of 







Annexe 14. Integrin activation and signaling. Low-affinity integrin has an inactive, bent, conformation (a). 
Integrin activation by cytoplasmic proteins or via ECM ligand (b), both lead to complete extension of the 
extracellular domains (c). High-affinity activated integrin and formation of focal adhesion (d). From Kyung Park 






Annexe 15. Schemes of commonly used migration assays. From Kramer, et al, Mutational Research (2013). 
 
